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Abstract 
 
Both chronic kidney diseases (CKD) with consecutive development of end stage renal disease 
(ESRD) and acute kidney injury (AKI) represent worrying problems for healthcare system 
due to its increased frequency and the lack of efficient treatments. Lysophosphatidic acid 
(LPA) is a bioactive lysophospholipid that elicits a wide range of cell responses (proliferation, 
migration, transformation, contraction etc.) through the activation of specific G protein-
coupled receptors (LPA1 to LPA6). In this work we were interested in involvement of the 
LPA and changes in its metabolism in CKD and AKI.  
Previous works showed that LPA exerts pro-fibrotic activity and contributes to development 
of tubulointerstitioal fibrosis (TIF) after ureteral obstruction through activation of LPA1 
receptors. In the first part of the thesis we were interested whether LPA signalization is 
involved in more advanced model of the disease. We found that 5 months after subtotal 
nephrectomy (SNX) mice develop massive albuminuria, TIF and glomerular hypertrophy 
compared to control animals. LPA concentration measured by liquid chromatography tandem 
mass spectrometry was increased in urine but not in plasma of animals. That increase in LPA 
significantly correlated with albuminuria and TIF. In addition we found a decreased renal 
expression of lipid phosphate phosphatases (LPP1, 2 and 3) that are responsible for the 
degradation of LPA by dephosphorylation.  Moreover, the expression of LPA1-LPA4 
receptors is down-regulated, whereas LPA5 and LPA6 are unchanged. We concluded here 
that the possible deleterious effect of LPA in the development of CKD in SNX mice was 
likely related to its increased production rather than an increased sensitivity of the kidney to 
LPA. 
Since LPA was reported previously to protect kidney damage in the course of 
ischemia/reperfusion injury, and that it was able to mitigate the systemic inflammation and 
organ damage in sepsis, we were interested in second part of the thesis to determine whether 
exogenous and/or endogenous LPA might protect against sepsis-associated AKI. C57BL/6 
mice were treated with exogenous LPA 18:1 1 hour before being injected with the 
lipopolysaccharide (LPS) and AKI was analyzed after 24h. LPA pre-treatment significantly 
mitigated the LPS-induced elevation of plasma urea and creatinine, lessened the up-regulation 
of inflammatory cytokines (IL-6, TNFα, MCP-1) and completely prevented the down-
regulation of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) 
in kidney. LPA also prevented LPS-mediated alterations of renal mitochondria ultrastructure. 
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In vitro, pre-treatment with LPA 18:1 (10 μM) significantly attenuated LPS-induced up-
regulation of the pro-inflammatory cytokines (TNFα and MCP-1) in RAW264 macrophages. 
In addition we found that LPS led to the reduction of urinary LPA concentration that was 
associated with a reduction in LPA anabolic enzymes (autotaxin and acylglycerol kinase), and 
an elevation in LPA catabolic enzyme (lipid phosphate phosphatase 2) expression in kidney 
cortex. We concluded hereby that exogenous LPA exerts protection against endotoxemia-
induced kidney injury. Moreover, the observation that LPS reduces the renal production of 
LPA suggests that sepsis-associated AKI could be mediated, at least in part, by alleviation of 
the protective action of endogenous LPA. 
In general our work shows that LPA local metabolism is altered in both forms of kidney 
diseases. In course of sepsis-induced AKI LPS leads to increased local catabolism of LPA 
leading to low availability of the phospholipid and alleviating its protective effect whereas in 
advanced CKD the local catabolism of the phospholipid is decreased with subsequent increase 
of urine LPA that favors development of the disease. Targeting LPA catabolism can be an 
interesting approach in treatment of kidney diseases.  
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Résumé 
 
Les maladies rénales chroniques (MRC) et l'insuffisance rénale aiguë (IRA) sont des 
problèmes essentiels de santé publique en raison de l’augmentation continue de leur fréquence 
et du manque de solutions thérapeutiques contre ces maladies. L'acide lysophosphatidique 
(LPA) est un lysophospholipide bioactif qui induit un large éventail de réponses cellulaires 
par le biais de récepteurs membranaires spécifiques (LPA1 à LPA6) couplés aux protéines G. 
Dans ce travail, nous nous sommes intéressés aux effets biologiques et au métabolisme du 
LPA dans les MRC et l’IRA. 
Des travaux antérieurs de l’équipe avaient montré que le LPA contribuait, via le récepteur 
LPA1, au développement de la fibrose tubulointerstitio (TIF) dans un modèle de MRC chez la 
souris : l’obstruction urétérale. Dans la première partie de la thèse nous avons étudié 
l’implication du LPA dans un modèle plus avancé de MRC: la néphrectomie subtotale (SNX) 
chez la souris. Nos travaux ont montré que 5 mois après chirurgie les souris (SNX) 
développaient une albuminurie massive associée à une TIF sévère et à une hypertrophie 
glomérulaire. Chez ces souris la concentration en LPA mesurée par chromatographie liquide 
en spectrométrie de masse en tandem était augmentée dans l'urine et étroitement corrélée à 
l'albuminurie et à la TIF. En parallèle, nous avons observé une diminution de l'expression 
rénale des Lipid-Phosphate Phosphatases (LPP 1, 2 et 3) responsables de l’inactivation du 
LPA. Nous avons également observé que l'expression rénale des récepteurs LPA1, 2, 3 et 4 
était diminuée chez les souris Snx. Nous avons conclu que les effets délétères éventuels du 
LPA dans le développement de la MRC chez les souris SNX était vraisemblablement lié à une 
augmentation de sa production rénale plutôt qu’à une sensibilité accrue du rein au LPA. 
Des travaux antérieurs avaient montré que l’injection de LPA protégeait contre l’apparition 
des lésions rénales induites par ischémie/reperfusion chez la souris. Une autre étude avait 
montré que le LPA permettait d’atténuer l'inflammation systémique et les dommages aux 
organes induits par un choc septique. Dans la deuxième partie de la thèse, nous avons étudié 
l’influence du LPA sur l’IRA induite par  une endotoxémie au LPS (lipopolysaccharide) chez 
la souris. Nous avons observé que l’injection de LPA permettait d’atténuer l'élévation d'urée 
et de créatinine plasmatiques, ainsi que l’augmentation d’expression rénale de cytokines  
inflammatoires (IL-6, TNFα, MCP-1) induites par le LPS. Le LPA a également empêché la 
baisse d’expression rénale du facteur PGC1α ainsi que les altérations ultra-structurales des 
mitochondries rénales induites par le LPS. In vitro, le LPA atténue l’augmentation 
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d’expression des cytokines pro-inflammatoires (TNFα et MCP-1) induite par le LPS dans les 
macrophages RAW264. Enfin, nos travaux ont montré que l’endotoxémie au LPS chez la 
souris entrainait une réduction de la concentration urinaire de LPA associée à une réduction 
des enzymes anaboliques LPA (autotaxine et acylglycérol kinase) et une élévation de 
l'expression de de LPP2, dans le cortex rénal. Nous en avons conclu que l'IRA associée à 
l’endotoxémie pourrait être liée, au moins en partie, à une réduction de la production rénale de 
LPA et, par voix de conséquence, de ses effets anti-inflammatoires protecteurs de la fonction 
rénale. 
En conclusion, notre travail montre que les variations de production rénale de LPA pourraient 
jouer un rôle important dans le développement des maladies rénales. L’augmentation du LPA 
dans les MRC favoriserait ses effets  délétères (fibrose, inflammation). Sa réduction dans 
l’IRA réduirait ses effets anti-inflammatoires. Cibler le catabolisme LPA pourrait donc être 
une approche intéressante dans le traitement des maladies rénales. 
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1. Introduction 
1.1 The kidneys 
The kidneys are paired bean-shaped organs located below the rib cage in retroperitoneal 
space. Their function is to filter plasma and remove waste products, regulate blood and 
electrolyte balance in the body (Figure 1). 
 
Figure 1.Location and structure of kidney (A) and structure of nephron (B)(adapted from 
OpenStax College, Anatomy and Physiology. OpenStax CNX). 
 
Histologically kidney consists of the renal cortex and renal medulla. Elementary structural 
and functional units of the kidney are nephrons, multicellular organizations found along 
cortex and medulla. The structures responsible for the filtration of the plasma and formation 
of primary urine are glomerules. Primary urine is further concentrated in kidney tubules, 
where some more products are reabsorbed or secreted.  
In addition to their filtration activities kidneys play an important role in maintaining body 
homeostasis by producing biologically active compounds such as renin (control of blood 
A B
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pressure), erythropoietin (stimulation of red blood cell formation in bone marrow), calcitriol 
(active form of vitamin D involved in maintenance of Ca2+ homeostasis). 
1.2 Kidney pathologies 
Historically diminished kidney function was classified as two distinct syndromes: acute 
kidney failure and chronic kidney failure. 
1.2.1 Acute kidney injury 
The concept of acute kidney failure is relatively new. Clinical characterization of patients was 
described during 2nd World War when occurrence of massive kidney function loss was 
realized after rhabdomyolysis (crush injury) [1]. Recently Acute Kidney Injury (AKI) has 
replaced the term acute renal failure to emphasize that a continuum of kidney injury occurs 
long before sufficient decrease of excretory kidney function can be detected. 
1.2.1.1 Definition and classification 
AKI is defined as a clinical syndrome characterized by rapid (over the course of hours to 
days) diminution of kidney excretory function and accumulation of waste products such as 
creatinine, blood urea nitrogen (BUN) or other toxins not measured routinely. Pathogenetic 
basis of the accumulation of these waste products is a rapid decline of glomerular filtration 
rate (GFR) caused by variety of etiologic factors. In addition, electrolyte (sodium, potassium, 
phosphorus) and fluid balance in body is largely altered in AKI. 
The proper staging of AKI is crucial since later stages of AKI are associated with an increased 
risk of death and the need for renal replacement therapy (RRT) increases. Different 
classifications of AKI were proposed. Initial criteria was based on the level of creatinine or 
glomerular filtration rate (GFR) proposed in 2004 (RIFLE) [2]. That classification was later 
modified and variations in diuresis have been taken into account in the classification proposed 
by Acute Kidney Injury Network (AKIN) [3]. The actually used classification was proposed in 
2012 by Kidney Disease International Global Outcomes group (KDIGO) [4] and uses a 
combination of previous two scores (RIFLE and AKIN) (Table 1).  
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Stage Serum creatinine Diuresis 
1 1.5-1.9 times baseline 
OR 
≥0.3mg/dl(≥26.5μmol/l) increase 
< 0.5 ml/kg/h for 6-12 hours 
2 2.0-2.9 times baseline < 0.5 ml/kg/h for ≥ 12 hours 
3 3.0 times baseline  
OR 
Increase in serum creatinine to  
≥ 4.0mg/dl (≥353.6 μmol/l) 
OR 
Initiation of renal replacement therapy 
OR , In patients < 18 years, decrease in 
eGFR to < 35 ml/min per 1.73 m2 
< 0.3 ml/kg/h for ≥ 24 hours 
OR  
anuria for ≥ 12 hours 
 
Table 1. KDIGO classification of AKI. 
Clinically AKI can be grouped into three primary types: prerenal, renal and postrenal [5]. 
(Figure 2) 
Prerenal. Maintenance of the normal GFR depends on adequate perfusion of the kidneys. 
Prerenal AKI is defined as decrease in GFR due to decline in renal perfusion pressure without 
initial intrinsic damage of the renal parenchyma. Kidneys receive up to 25% of cardiac output 
and any decline in general or local, intrarenal circulation can alter kidney function. Causes of 
prerenal AKI are hypovolemia (hemorrhage, diarrhea, vomiting etc.), impaired cardiac output 
(congestive heart failure, pericardial tamponade etc), decreased vascular resistance and 
vasodilation (sepsis, vasodilatators etc). Rapid restoration of intravascular volume will 
improve kidney function. However if decline in kidney perfusion is long enough it can lead to 
ischemic kidney disease indicating that there could be a continuum from prerenal to renal 
AKI [5, 6]. 
Renal. There is a broad list of factors that cause renal type of AKI. Theoretically damage to 
all different kidney structures can cause AKI. Acute tubular necrosis (ATN) is the histological 
hallmark of AKI due to damage to kidney tubules and can be caused most frequently by 
ischemia (caused by severe decline in renal perfusion) or nephrotoxic agents (exogenous such 
as aminoglycosides, radiocontrast media, etc. or endogenous such as myoglobin in 
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rhabdomyolysis etc). Glomerular damage (in severe cases of glomerulonephritis), interstitial 
(interstitial nephritis due to an allergic reaction to drugs or to an infection) and vascular 
alterations (damage to intrarenal vessels due to malignant hypertension, hemolytic-uremic 
syndrome etc.) are other possible mechanisms for the development of renal AKI [5, 6]. 
Postrenal. Postrenal AKI is caused by acute obstruction of urine flow that increases 
intratubular pressure and decreases GFR. Obstruction of the urinary tract at any level may 
produce AKI. However obstruction must concern the 2 kidneys or a solitary kidney to get 
AKI development (benign prostatic hyperplasia, prostatic or gynecological cancers, 
retroperitoneal fibrosis, urolithiasis etc.) [5, 6]. 
 
 
 
Figure 2.Etiologies of AKI (adapted from [6]). 
 
Prerenal AKI Renal AKI Postrenal AKI
Acute kidney
injury
Tubular
damage
Glomerular
damage
Interstitial
damage
Vascular
damage
Ischemic Nephrotoxic
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1.2.1.2 Epidemiology of AKI  
The incidence of AKI is continuously increasing. The number of hospitalizations for dialysis-
requiring AKI increased from 63000 to 164000 and the population incidence rate of dialysis-
requiring AKI increased from 222 to 533 cases/million person-years between 2000 and 2009 
years in US [7]. The total number of inpatient deaths associated with dialysis-requiring AKI 
increases in parallel to incidence rate from 18000 in 2000 to 39000 in 2009[7]. Incidence of 
AKI is especially high in intensive care settings and can rich up to 67% [8]. In 47.5% of 
critically ill patients in intensive care units (ICU) AKI was associated with sepsis representing 
the most common contributing factor of AKI in ICU patients [9]. Patients with sepsis develop 
more severe AKI, are more likely to receive RRT, display less frequency of renal function 
recovery, longer ICU stay and higher ICU mortality [8, 10]. From the economical point of 
view AKI is a big burden to healthcare systems since reported hospitalized patients increase 
hospital costs compared to patients who did not develop AKI due to the long ICU stay with 
greater number of investigations and monitoring as well as RRT use [11]. 
1.2.1.3 Sepsis-induced AKI 
Despite the high incidence and increased mortality, molecular pathways and mechanisms 
mediating sepsis-induced AKI are poorly defined and no specific targeted therapies exist. The 
pathogenesis of septic AKI is very complex and involves pathobiological events such as 
microcirculatory changes with endothelial disturbances and changes in coagulation cascade, 
inflammation, oxidative stress and adaptive cell response to injury.  
Histological changes in septic AKI are sparse and moderate and do not explain the clinical 
phenotype observed in patients. Tubular cell injury is heterogeneously distributed along 
kidney and nonspecific changes are more prominent such as apical vacuolization, loss of 
brush border, tubular cell swelling. Tubular epithelial cell death is rather mediated by the 
mechanism of apoptosis than necrosis in contrast to ischemic and toxic AKI, where ATN is 
the prominent histopathological finding [12, 13].  
1.2.1.3.1 Pathogenesis of sepsis-induced AKI 
1.2.1.3.1.1 Hemodynamic changes 
Traditionally AKI development in patients with sepsis was attributed to hemodynamic 
changes secondary to a mismatch between kidney demand and perfusion. Decreased renal 
blood flow (RBF) due to systemic vasodilatation and decreased systemic vascular resistance 
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were considered as leading factors that cause diminution in kidney perfusion in conditions of 
increased kidney metabolic demand due to sepsis. There are conflicting results in studies 
using animal models of sepsis regarding RBF changes in septic AKI with some studies 
indicating decreased RBF, whereas others declared unchanged or even increased RBF. More 
recent studies indicated development of AKI in septic animals in parallel with increased RBF 
and renal vasodilatation [14, 15]. Number of human studies that directly measured RBF by 
invasive techniques remains low and in all studies RBF was preserved or increased during 
septic AKI [16]. In addition, Murugan et al showed in their prospective study that AKI is a 
common finding in patients with community-acquired non severe pneumonia and could 
develop even in patients who do not present any signs of hemodynamic instability and were 
not transferred to ICU unit [17]. Today it is generally accepted that GFR decline and AKI 
development in sepsis are not attributed to decreased RBF but can happen even in case of 
increased RBF; the term so-called hyperemic AKI was proposed [18].  
Further studies showed that the major hemodynamic alterations in kidneys of septic-AKI are 
in the level of microcirculation. Especially it was shown that there is a decrease in renal 
capillaries with continuous flow and a parallel increase in capillaries with intermittent or no 
flow [19, 20]. Studies in porcine model of sepsis showed that in conditions of overall 
increased RBF, cortical microvascular perfusion was decreased due to shunting of cortical 
blood flow towards medulla and renal perfusion pressure was significantly decreased due to 
increased renal venous pressure [21]. In addition, a retrospective observational study showed 
that elevated central venous pressure was associated with progression to AKI in septic 
patients suggesting that venous congestion plays a role in septic AKI [22].  The pathogenic 
basis of microcirculatory changes in septic kidneys could be the endothelial dysfunction 
leading to vasoconstriction which, in parallel with activation of platelets and coagulation 
cascade, can cause capillary occlusion. As a result, vascular permeability increases causing 
interstitial edema, which in turn leads to increased venous pressure and affects GFR.  
These data can indicate that microcirculatory alterations and increased renal venous pressure 
with further decrease in renal perfusion pressure rather than decrease in overall RBF are 
important in underlying hemodynamic changes in septic AKI.  
It is important to mention here that nitric oxide (NO) also plays a role in septic AKI. The 
inducible NO synthase (iNOs) is constitutively expressed in kidney and its expression is 
induced during sepsis [23]. Synthesized NO can exert different actions. On one hand it can 
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lead to systemic vasodilatationand hemodynamic instability with further activation of 
sympathetic system and release of angiotensin. This in turn can lead to constriction of 
intrarenal vessels with resulting decrease in GFR [24]. On the other hand, reacting with 
reactive oxygen species (ROS) produced in sepsis, NO can be converted to peroxynitrite 
(ONOO-) that is a potent oxidant molecule that could be responsible for oxidative stress 
development and cytotoxic effects of NO. Selective inhibitors of iNOS showed some 
protective effect in sepsis-induced AKI [25, 26].  
1.2.1.3.1.2 Inflammation in sepsis-induced AKI 
Sepsis is considered as a hyper-inflammatory condition with “cytokine-storm” as a response 
to the pathogen. In sepsis, pathogen triggers a host response in which inflammatory 
mechanisms contribute to clearance of infection and tissue recovery on one hand and to organ 
damage on the other hand. Inflammation is initiated when cells of innate immune system 
recognize highly conserved pathogen-associated molecular patterns (PAMP) such as 
lipopolysaccharide (LPS). Pattern-recognition receptors including toll-like receptors (TLR), 
C-type lectin receptors (CLR), nucleotide-binding oligomerization domain like receptors 
(NOD-like receptors) and retinoic acid inducible gene 1-like receptors (RIG-1-like receptors) 
are responsible for the recognition of PAMPs [27]. These receptors also recognize 
endogenous molecules released from injured cells known as damage-associated molecular 
patterns (DAMPs) (DNA, RNA, histones, etc.). The engagement of these receptors results in 
up-regulation of inflammatory gene transcription and initiation of immune response. Different 
cytokines such as TNFα, IL6, IL10 are found in high concentrations in septic patientsand 
there is a positive correlation between the level of the cytokines and sepsis-induced AKI [17, 
28].  
Synthesized cytokines activate different types of cells such as leukocytes, endothelial cells, 
platelets, epithelial cells. Activated endothelial cells up-regulate expression of adhesion 
molecules such as E-selectin, P-selectine, intercellular adhesion molecule 1 (ICAM-1) and 
vascular cell adhesion molecule 1 (VCAM-1) [29-31]. Increased expression of adhesion 
molecules in parallel with microvascular changes and sluggish blood flow promotes leukocyte 
adhesion to endothelial cells, leads to increased leukocyte transit through kidney capillaries 
and increases the general leukocyte recruitment into kidney. These activated leukocytes in 
turn produce different bioactive molecules (ROS, proteases, elastases etc.) that contribute to 
further tissue damage. Leukocytes that leave peritubular capillaries are in close proximity 
with tubular epithelial cells and can activate these cells directly by releasing pro-inflammatory 
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mediators and DAMPs locally. Interestingly epithelial cells can also be activated by the 
tubular side as PAMPs, DAMPs and pro-inflammatory cytokines can be filtered in glomerulus 
and reach the tubular epithelial cells. Recognition of DAMPs and PAMPs in epithelial cells 
can be mediated through TLR receptors that were expressed in murine and human kidney 
tubules [32]. TLR-4 receptors play important role in tubular epithelium as they are 
responsible for the recognition and internalization of luminal LPS [33, 34]. Downstream to 
TLR-4 activation could be the activation of the transcription factor NF-κB leading to 
subsequent increased production of cytokines and enahanced inflammatory signal. After 
internalization of LPS, epithelial cells in S1 segment of proximal tubules signal in a paracrine 
fashion to more distally located epithelial cells and cause oxidative stress in neighboring S2 
segment thus giving to the cells of S1 segment properties of sensor for danger signals [34]. 
Distally located epithelial cells change their metabolism to adapt to a potentially lethal new 
situation (Figure 3). It remains however not completely understood how TLR-4 activation and 
induction of downstream inflammatory cascade could lead to decreased GFR and AKI 
development. One possible mechanism explaining this phenomenon could be the altered 
electrolyte transport in proximal tubules caused by sepsis with increased delivery of sodium 
and chloride to macula densa that causes enhanced tubuloglomerular feedback resulting in 
decreased GFR [35]. 
 
Figure 3. Schematic presentation of sepsis-induced microcirculatory changes and recognition 
of DAMPs/PAMPs by proximal tubular epithelial cells. Taken from [36]. 
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1.2.1.3.1.3 Adaptive responses in tubular epithelial cells 
The oxidative stress and inflammatory processes trigger responses in tubular epithelial cells 
that are adaptive in their nature. These adaptive responses lead to conservation of existing 
energy with expenditure only in processes crucial for cell survival. This “energy conserving” 
adaptive response of tubular epithelial cells is regulated by mitochondria. It was shown that 
oxygen consumption by kidney tubular epithelial cells is reduced in septic conditions and was 
mediated by peroxisome proliferator-activated receptor gamma (PPARγ) coactivator 1α 
(PGC1α), a major regulator of mitochondrial biogenesis and metabolism. PGC1α was 
significantly down-regulated in kidneys of septic animals exposed to LPS, whereas increased 
expression of PGC1α was associated with restored oxygen consumption and improved kidney 
function [37, 38]. Another component of adaptive cell response in septic kidneys is cell cycle 
arrest. It was shown that cell cycle arrest in G1-S checkpoint is associated with kidney injury 
and the recovery of kidney function is associated with cell cycle progression within 48 hours 
[39]. In agreement with this, two molecules known as markers of cell cycle arrest (tissue 
inhibitor of metaloproteinases 2 and insulin-like growth factor-binding protein 7) are efficient 
biomarkers in assessing the risk of development of AKI in critically ill patients [40]. Limiting 
cell replication conserves energy levels and prevents cells from undergoing an energetically 
overtaxing behavior that can trigger cell death. One more adaptive response in tubular cells is 
the process of mitophagy, a process of removal and autodigestion of damaged mitochondria. 
It was shown that mitophagy is induced very early during sepsis in kidney by different factors 
including inflammation and oxidative stress and that decreased mitophagy is associated with 
proximal tubular dysfunction and overall worse outcome in critically ill patients [41, 42]. The 
biological role of mitophagy is to eliminate the injured mitochondria with subsequent 
diminution in ROS production and again energy conservation. 
It is assumed now that the clinical phenotype of AKI is the early expression of the adaptive 
response of tubular cells to injurious signal. The inflammatory response and the oxidative 
stress during sepsis cause an adaptive response in tubular epithelial cells with a down-
regulation of cell function aiming to reduce energy consumption and to ensure cell survival. 
As a result kidney function is reduced [43].  
1.2.1.3.2 Treatment strategies 
Treatment strategies targeting several pathogenic loops of sepsis were proposed previously. 
Targeting inflammatory cytokines TNFα [44], IL1β [45] as well as LPS [46] and TLR-4 
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receptors [47] were tested. Neither of these strategies was proven as an efficient treatment 
option for sepsis or associated complications. In preclinical studies, various molecules 
displayed protective effects during sepsis-induced AKI (resveratrol [19], 2-methoxyestradiol 
[48], temsirolimus [49], alkaline phosphatase [50], aminoguanidine and methylguanidine [25, 
26], pentoxyfilline [51]). Protective effect of alkaline phosphatase was proven in phase IIa 
clinical trial and if benefits are proven in large-scale studies it could be a promising treatment 
approach for sepsis-induced AKI [52]. Despite a better comprehension of the pathogenesis of 
sepsis-induced AKI and proposed different treatment modalities, pathogenic curative methods 
are not available so far and the only strategy combating sepsis-induced AKI remains RRT.  
1.2.2 Chronic kidney disease 
1.2.2.1 Definition and classification 
Chronic kidney disease (CKD) is defined as abnormalities of kidney function or structure 
present for more than 3 months, with implications for health [53]. In contrast to relatively 
short history of AKI, CKD was identified long time ago (in 19th century) however 
pathogenetic treatment is not developed so far. In severe failure RRT (peritoneal dialysis or 
hemodialysis, or kidney transplantation) is the only option. KDIGO classified CKD in 5 
stages depending on the severity of the disease, based mainly on measured or estimated GFR 
[53]. In Stage 1 kidney function is reserved and in Stage 2 it is reduced minimally. RRT is 
generally initiated in Stage 5.  
GFR stage Description  GFR (mL/min/1.73m2) 
1* Normal or high ≥90 
2* Mildly decreased 60-89 
3A Mildly to moderately decreased 45-59 
3B Moderately to severely decreased 30-44 
4 Severely decreased 15-29 
5 Kidney failure <15 
 
Table 2. GFR categories of CKD proposed by KDIGO [53]. 
*In the absence of kidney damage neither stage 1 nor stage 2 fulfill the criteria for CKD 
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In 2012 it was proposed by KDIGO to include the levels of albuminuria (Table 3) and the 
cause of the CKD in the classification as they can affect the outcomes and the choice of 
treatment.  
Albuminuria stage Definition 
Albumin excretion rate 
(mg/24 hours) 
1 Normal to mildly increased <30 
2 Moderately increased 30-300 
3 Severely increased >300 
 
Table 3. Albuminuria categories in CKD proposed by KDIGO [53]. 
CKD can develop in case of any damage in any structural compartments of kidney: 
glomerules, tubulo-interstitium or vasculature. Many factors acting on kidneys can cause 
CKD such as metabolic, ischemic, immunologic, toxic, hereditary, mechanical etc. CKD can 
develop as a consequence of systemic diseases (diabetes mellitus, arterial hypertension, 
autoimmune diseases, systemic vasculitis etc.) or can be the result of a primary kidney disease 
(glomerulonephritis, focal-segmental glomerulosclerosis, cystic diseases of kidneys etc.). 
Diabetes is the leading cause of CKD in developed and developing countries where the 
second most common cause is hypertension [54]. In countries with low income, the major 
cause is glomerulonephritis or the etiological factors remain unknown [54]. The differences in 
causative factors of CKD in different areas are due to moving the disease burden from 
infectious towards chronic lifestyle-related diseases,increased life-expectancy and decreased 
births in developed countries, whereas infectious diseases continue to be prevalent in 
countries with low-income due to poor sanitation, inadequate supply of safe water and high 
concentrations of disease-transmitting vectors [54]. 
1.2.2.2 Epidemiology of CKD 
CKD is one of the major public health problems worldwide and with its final stage (end stage 
renal disease, ESRD) represents a huge burden to healthcare systems. According to the Global 
Burden of Diseases study, CKD is among the top three fastest growing main causes of death 
worldwide, behind HIV/AIDS and diabetes mellitus. The absolute number of deaths from 
CKD has increased by 82% between 1990 and 2010 [55]. Age-standardized death rates from 
CKD increased by 15% in this period while rates for most diseases fell, including other non-
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transmissible diseases such as major vascular diseases, chronic pulmonary disorders, most 
forms of cancer and liver cirrhosis [55]. It was observed that for most non-transmissible 
causes of death, the global increase in the number of deaths was due to ageing of the 
population, while for CKD both ageing of the population and ageing-independent factors were 
contributing [55]. CKD is associated with an increased risk of dying from cardiovascular 
causes (including ischemic heart disease, cerebrovascular diseases, heart failure, arrhythmias), 
but also from non-cardiovascular causes such as infections, neurologic disorders, cancer [56]. 
Despite these worrying epidemiologic data pathogenetic or regression-inducing treatments are 
not available and the RRT remains the only option for developed ESRD thus representing a 
huge economical problem for healthcare systems. About 2-3% of healthcare expenditure in 
developed countries is used to provide treatment to patients with ESRD [54]. 
1.2.2.3 CKD pathogenesis 
As mentioned above multiple causative factors can underlie the development of CKD. 
Whatever the nature of the initial injury, the final common manifestation of many CKDs is 
renal fibrosis. Like in other organs, fibrosis in kidney is characterized by a succession of 
events which initial final biological aim is to regenerate damaged tissue. Fibrosis is a 
deregulated form of fibrogenesis characterized by excessive extracellular matrix (ECM) 
accumulation that leads to the alteration of tissue architecture and ultimately function loss. 
Kidney fibrosis comprises the processes of glomerulosclerosis, tubulo-interstitial fibrosis 
(TIF) or the combination of both. 
1.2.2.3.1 Glomerulosclerosis 
Two most common causes of CKD (diabetes mellitus and hypertension) as well as a big group 
of primary glomerulopathies and glomerular alterations due to systemic autoimmune diseases 
are characterized by initial alterations of glomerules. The initial insult is on glomerular 
endothelium causing activation and dysfunction of endothelial cells, hemodynamic alterations 
and loss of glomerular basement membrane (GBM) electrical charge. Later the glomerular 
inflammatory reaction is initiated leading to interaction between inflammatory and mesangial 
cells causing activation, proliferation and dysfunction of the latter. Under the influence of 
inflammatory cytokines (especially TGFβ) mesangial cells undergo phenotypic changes with 
the formation of cells with embryonic mesenchymal phenotype (mesangioblast). These cells 
are capable of excessive ECM production leading to mesangial expansion. Another feature of 
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glomerular damage is podocyte injury with decreased podocyte number, foot process 
effacement and denudation of glomerular basement membrane. Persistent and continuing 
insult to endothelial-mesangial-epithelial axis will lead to cell death by apoptosis and 
replacement of glomerular cells by ECM with the final development of glomerulosclerosis 
[57, 58]. 
1.2.2.3.2 Tubulo-interstitial fibrosis (TIF) 
Even though the majority of CKDs initiates with the glomerular damage and are associated 
with glomerulosclerosis, the fibrosis develops thereafter towards tubulo-interstitial 
compartment. Moreover there is a strong association between renal functional impairment and 
the level of TIF in patients with primary glomerular alterations [59].  Various mechanisms 
underlie development of the TIF after initial glomerular damage. Abnormally-filtered proteins 
including albumin, complement and cytokines activate tubular cells and initiate an 
inflammatory response. In parallel hemodynamic alterations lead to decreased post-
glomerular blood flow to peritubular capillaries leading to hypoxic damage of tubular 
epithelium.  
The TIF is a complex processes that involves inflammation, appearance of ECM producing 
cells and eventual ECM accumulation.  
1.2.2.3.2.1 Inflammation 
The striking histological feature of TIF is interstitial inflammatory infiltrate consisting of 
different inflammatory cells. Increased expression of chemokines (CCL2/MCP1, 
CCL5/RANTES) and adhesion molecules (E and P selectins, ICAM-1, VCAM-1) by kidney 
resident cells regulate leukocyte recruitment into kidneys. Moreover, targeting MCP-1 and its 
receptor CCR2 [60-62] as well as P-selectin [63], ICAM-1 [64, 65] protects against fibrosis in 
different models of kidney diseases. Although a small population of resident interstitial 
macrophages may proliferate in response to renal injury, most of the inflammatory cells are 
recruited from circulation. Recruited monocytes trans-differentiate into macrophages in 
kidney interstitium. There is a strong correlation between macrophage infiltration and the 
extent of fibrosis whereas depletion of macrophages ameliorates fibrogenesis in mice [66, 67]. 
Macrophages can be categorized into classically activated M1 macrophages and alternatively 
activated M2 macrophages. The M1 macrophages are mostly implicated in formation of ROS 
and pro-inflammatory cytokines (TNFα, IL1β) which in high concentrations could be 
detrimental for resident cells [68]. In contrast M2 macrophages produce anti-inflammatory 
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cytokines such as IL10 and proteins of ECM (fibronectine) playing role in tissue repair. These 
cells produce also pro-fibrotic cytokines transforming growth factor β (TGFβ) and connective 
tissue growth factor (CTGF) which promote accumulation and activation of myofibroblasts 
[68].  
The other types of recruited inflammatory cells are lymphocytes, mast cells, dendritic cells. 
Role of lymphocytes in CKD development was shown in different models [69-71], whereas 
mast cell involvement remains controversial. While some studies indicate that mast cell 
depletion enhances kidney fibrosis upon ureteral obstruction [72] or puromycine-induced 
glomerulonephritis [73] indicating possible protective role of these cells, another study 
showed that mast cells participate in the aggravation of glomerular lesions and kidney 
function loss in experimental model of crescentic glomerulonephritis [74]. The precise role of 
dendritic cells in kidney fibrosis is not yet fully understood.  
1.2.2.3.2.2 Appearance of ECM producing cells 
Myofibroblasts in the renal interstitium are considered as the principal source of fibrillar 
matrix. Schematically myofibroblasts are activated fibroblasts that express alpha smooth 
muscle actin (αSMA).  Sources of myofibroblasts in kidney fibrosis are different: 
x The normal interstitium is populated by small number of fibroblasts that are residual 
embryonic mesenchymal cells and that are relatively quiescent. Under the influence of 
different molecules released in inflammatory conditions (TGF, fibroblast growth factor-2 
(FGF-2), CTGF etc.) resident fibroblasts may proliferate and undergo phenotypic 
transformation acquiring fibrosis-promoting characteristics [75].  
x Another source of myofibroblasts are circulating fibrocytes, that are bone marrow-
derived cells expressing leukocytes (CD34 or CD45) and mesenchymal (collagen I or 
vimentne) markers [76]. While ECM production of fibrocytes is relatively low, they produce 
large amounts of collagen and fibronectine after transformation into myofibroblasts [76].  
x One more important mechanism responsible for the appearance of myofibroblasts is 
the so called epithelial mesenchymal transition (EMT) during which epithelial cells 
dedifferentiate into matrix producing fibroblasts and myofibroblasts. It was estimated that 
during CKD progression about 30% of fibroblasts in kidneys are derived from EMT [77, 78]. 
In response to inflammatory cytokines tubular cells show down-regulation of their epithelial 
and up-regulation of a mesenchymal genetic program resulting in a loss of epithelial markers 
such as E-cadherin, zonula occludens-1, cytokeratine and acquisition of mesenchymal 
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markers such as vimentin, matrix metalloproteinase-2, fibroblast specific protein-1, type I 
collagen and fibronectine. In addition epithelial cells undergo phenotypic changes such as loss 
of epithelial cell adhesion and polarity, actin reorganization and αSMA expression, tubular 
basement membrane disruption and increased cell migration and invasion [79].  
x Another source of kidney fibroblasts are endothelial cells that undergo transcriptional 
reprogramming under certain conditions and regain characteristics of matrix producing 
fibroblasts (endothelial mesenchymal transition) [80].  
1.2.2.3.2.3 Pro-fibrotic cytokines 
TGFβ: It is a pleiotropic cytokine that controls various cellular processes such as 
proliferation, differentiation and apoptosis and participates in number of physiological and 
pathological processes such as angiogenesis, immune processes, tissue reparation, cancer etc 
[81].  It has strong pro-fibrotic potential and is a key molecule in kidney fibrosis [82]. TGFβ 
stimulates ECM production and its strong up regulation is described in number of kidney 
pathologies. Its exogenous administration induces kidney fibrosis, whereas TGFβ 
signalization blockade attenuates progression of fibrosis [82]. This molecule acts through 
activation of TGFβ type I or type II receptors and phosphorylation of cytoplasmic Smad 
proteins which translocate to the nucleus and activate target genes [82].  
CTGF (CCN2): It is a secreted growth factor that is implicated in various physiologic 
processes such as angiogenesis, osteogenesis, tissue repair but also in pathologic conditions 
such as fibrosis and cancer [83].  It was shown that CTGF induces EMT, promotes production 
of chemokines and pro-inflammatory cytokines from epithelial cells, recruitment of 
macrophages, differentiation of fibroblasts to myofibroblasts and ECM production acting 
alone or in combination with other cytokines like TGFβ [84, 85]. CTGF expression increases 
in the zones of TIF in kidneys of patients with different forms of nephropathies [86]. 
Interestingly there is a crosstalk between actions of CTGF and TGFβ: while TGFβ 
upregulates CTGF expression in different cell types, CTGF itself modulates TGFβ action by 
activating latent TGFβ and favoring binding of  TGFβ to its receptor[87].  
1.2.2.3.2.4 Accumulation of ECM 
Accumulation of ECM proteins within kidney interstitium is a dynamic process that changes 
over time by intensity and macromolecular composition. Early phases of fibrosis are 
characterized by accumulation of loose connective tissue composed of fibronectine and 
collagen type I and III that are sensible to degradation [88]. In advanced stages glycoproteins, 
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proteoglycans and components of basal membrane (laminine, collagen type IV) appear and 
the proteins undergo irreversible reticulation making the matrix more rigid and more resistant 
to proteases [88]. 
The normal kidneys contain proteases that are implicated in matrix degradation and keep the 
dynamic balance between synthesis and degradation of ECM. Among them, the matrix 
metalloproteinase 2 and 9 (MMP2 and MMP9) as well as the serine proteases urokinase-
plasminogen activator (uPA) and the tissue plasminogen activator (tPA) are known. During 
fibrosis expression of plasminogen activator inhibitor-1 (PAI-1, a specific inhibitor of uPA 
and tPA) as well as tissue inhibitor of metalloproteinase 1 (TIMP-1, a specific inhibitor of 
MMPs) are increased [89, 90]. As a result ECM degradation is inhibited and the balance leans 
towards ECM accumulation.  
Important steps in the development of TIF are schematically presented in Figure 4.  
 
Figure 4. Development of TIF (adapted from [91]). 
 
Glomerulus
Insults:
toxic, immunologic,infectious, metabolic, 
ischemic
TTubular epithelialcells
Inflammation Hypoxia
Leakage of albumin and 
complement proteins
Endothelial
dysfunction
Proinflammatory
cytokines
Secretion Growth factors Transdifferentiation Chemokines, adhesion
molecules
Cytokines, growth
factors
Leukocytes
Growth factors
Extracellular matrix Myofibroblasts
Fibrosis
29 
 
1.2.2.4 Progression of CKD  
Once fibrosis takes place, an apparently irreversible course towards ESRD occurs. That 
process is very complex and multiple factors are involved. It is important to notice that the 
majority of factors responsible for the development of fibrosis in kidneys are also responsible 
for the progression of the diseases. The major pathogenic contributors of progression are 
shortly presented: 
x Cytokines and growth factors-Sustained tissue aggression and chronic inflammation 
lead to increased amounts of different chemokines, cytokines and growth factors which in 
turn aggravate fibrosis. In addition to the action of TGFβ and CTGF, platelet derived growth 
factor (PDGF) [92], FGF-2 [93], epidermal growth factor receptors (EGFR) are increased in 
kidney fibrosis and promote progression of the disease. In addition the expression of anti-
fibrotic molecules such as hepatocyte growth factor [94] or bone-morphogenic protein-7 is 
decreased [95] therefore amplifying fibrosis. 
x Activation of renin-angiotensin-aldosterone system (RAAS)-The RAAS plays an 
important role in the control of arterial blood pressure. That system not only plays a critical 
role in regulation of intraglomerular hemodynamic, but also shows pro-fibrotic activities 
through multiple mechanisms independent from those involved in their hemodynamic activity 
[96].  
x Proteinuria- The presence of proteins in urine results from damaged glomerular 
filtration barrier. Proteinuria leads to further tubulo-interstitial damage by different 
mechanisms: 1) excess reabsorbtion in the proximal tubular cells and lysosomal rupture, 2) 
direct cytotoxic effect of plasma proteins through induction of ROS, chemokine and adhesion 
molecule production, 3) co-excretion of complement proteins and different pro-fibrotic 
molecules (the most important is TGFβ) [97]. 
x Hypoxia- In biopsy specimens from CKD patients, rarefaction of peritubular 
capillaries is demonstrated. The progressive loss of microvasculature in parallel with CKD-
associated anemia contribute to tissue hypoxia which in turn promotes progression of fibrosis 
through induction of fibroblast proliferation and differentiation into myofibroblast, increased 
ECM production and EMT [98].  
1.2.2.5 Therapeutic strategies 
Clinical studies, trials and preclinical investigations over the last several decades have 
demonstrated that inhibition of RAAS with angiotensin converting enzyme inhibitors (ACEIs) 
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and angiotensin AT-1 receptor antagonists (ARA) is the most effective single therapy to 
attenuate progression of CKD [99]. The use of RAAS blockers is the first line treatment of 
diabetic and non-diabetic kidney diseases. Unfortunately, despite those treatments, CKD 
continues very often to progress. Alternative molecules or therapies capable to block or even 
reverse fibrosis are thus necessary. For ESRD the only available treatment option is RRT.  
 
1.2.3 AKI and CKD are interconnected 
For many years, AKI and CKD were considered as two distinct syndromes. However recent 
epidemiologic studies suggest that these two syndromes are closely interconnected in a 
continuum [100]. 
1.2.3.1 AKI is a risk factor for CKD 
It was considered for long time that patients were completely recovered after AKI. However 
different studies suggested that the kidney function of patients following AKI is altered 
increasing the risk of later CKD development. It is now considered that women with a history 
of preeclampsia (gestational pathology characterized by elevated arterial pressure and 
vascular kidney injury) have an approximate 5-12 fold increased risk for ESRD development 
later in life [101]. Another study demonstrated more than 40 fold increased risk of ESRD in 
patients with pre-existing CKD who suffered AKI episodes compared to healthy individuals. 
The risk of ESRD is only 8 fold higher in CKD patients without AKI episode [102]. This 
suggests that AKI triggers signals that are responsible for CKD installation.   
Severity and occurrence of multiple AKI episodes is associated with CKD progression 
whereas duration of the AKI episode seems to be linked to global mortality rather than to 
CKD progression [103].  
1.2.3.1.1 The mechanisms of AKI progression to CKD 
Numerous mechanisms are proposed to explain development of fibrosis following an episode 
of AKI: 
x Nephron loss and glomerular hypertrophy- After an episode of AKI, it is possible that 
a significant permanent loss of nephron mass results in a compensatory hyperfiltration and 
glomerular hypertrophy in remaining nephrons. Cellular proliferation ensues and ultimately 
results in TIF and progressive nephron loss [100]. 
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x Interstitial inflammation and fibrosis- Inflammation has been shown to be an 
important feature of ischemic and septic AKI with the biological aim to remove the causative 
agent and to induce tissue regeneration. In most models of experimental AKI, renal tubular 
regeneration occurs. If the alteration is severe enough the recovery is often not complete and 
the areas of incomplete recovery become fibrotic [100].  
x Tubular epithelial repair- In most models of experimental AKI, renal tubular 
regeneration occurs. Normal repair processes involve multiple growth factors and 
proliferative and other signaling cascades, which must function in temporally and spatially 
coordinated manner. These mechanisms are critical for appropriate repair and regeneration. 
Large number of tubular epithelial cells arrested in G2/M phase of the cell cycle is displayed 
when kidney injury is accompanied by fibrosis [104]. These arrested cells in opposite to 
proliferating cells produce greater amounts of TGFβ and CTGF that trigger fibrosis 
development.   
x Endothelial injury and vascular rarefaction- While tubular repair after AKI is robust, 
the restoration capacity of vasculature remains blunted [105]. Different AKI experimental 
models demonstrate diminished vascular density (30-50%) after injury [100]. The injured 
tissue becomes hypoxic due to insufficient vascular supply and this initiates pro-inflammatory 
and pro-fibrotic changes.  
 
1.2.4 Conclusions 
Despite better understanding the pathogenetic mechanisms involved in the development of 
both forms of kidney pathologies, treatment modalities are sparse. New researches are 
conducted all over the world with the aim to raise new approaches to treat these diseases.   
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2. Lysophosphatidic acid 
2.1-Structure 
Lysophosphatidic acid (LPA) is a bioactive lipid mediator present in intracellular and 
extracellular compartments that is capable to regulate number of cellular functions and that is 
associated with increasing numbers of pathologies. LPA is made of a glycerophosphate 
backbone esterified (acyl or alkyl bond) at its sn1 (Figure 5A) or sn2 (Figure 5B) position 
with a fatty acid. There exist different molecular species of LPA depending on the length and 
saturation of the fatty acid chain moiety [106]. 
 
Figure 5: Structure of oleoyl-LPA with the C18:1 fatty acid chain esterified (acyl bond) at the 
sn1 (A) or sn2 (B) position. 
 
2.2 Synthesis of LPA 
LPA can be produced either in intracellular or in extracellular compartment. 
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2.2.1 Intracellular synthesis 
LPA is an essential metabolite intermediate of triglyceride and phospholipid anabolism in 
various cell types and is synthesized through the action of glycerol-3-phosphate 
acyltransferase (GPAT) on glycerol 3-phosphate found mainly in mitochondria and 
endoplasmatic reticulum [107, 108]. LPA is then converted to phosphatidic acid (PA) by 
LPA-acyltransferase (LPAAT) and further to different phospholipids (PL) and triglycerides 
(TG) [109]. 
Intracellular LPA can also be synthesized by the action of intracellular phospholipases A1 or 
A2 (PLA1 and PLA2) that convert PA to LPA by the hydrolytic cleavage of the bond between 
fatty acid chain and glycerol backbone at sn1 (PLA1) or sn2 (PLA2) positions [110].  
One more pathway for intracellular synthesis is the phosphorylation of monoacylglycerol to 
LPA by the catalytic action of monoacylglycerol kinase (MAGK) [111]. 
A recent study showed that two members of intracellular glycerophosphodiester 
phosphodiesterase family, GDE4 and GDE7, possess a lysophospholipase D activity and can 
produce LPA acting on different substrates such as LPC and lyso-PAF [112].   
2.2.2 Extracellular synthesis 
Two major pathways of extracellular LPA synthesis have been described so far.  
In the first pathway PA is first produced from diacylglycerol through the action of 
diacylglycerol kinase (DAGK) or from other PLs (ex. phosphatidylcholine (PC) or 
phosphatidylethanolamine (PE)) through the action of phospholipase D (PLD). PA synthesis 
occurs mainly in the inner leaflet of the plasma membrane. Synthesized PA is further 
translocated to the outer leaflet of plasma membrane where it can be deacylated by secreted 
phospholipase A2 (PLA2) [113] or PA-specific phospholipase A1 (PA-PLA1α and PA-PLA1β 
also known as LIPH and LIPI respectively) [114, 115] to generate LPA (see Figure 6). 
In the second pathway, different lysophospholipids (LPL) such as lysophosphatidylcholine 
(LPC), lysophosphatidylethanolamine (LPE), lysophosphatidylserine (LPS) are first produced 
by the hydrolytic cleavage of a fatty acid from their respective phospholipids through the 
action of secretory phospholipase A2 or phosphatidylserine (PS)-specific PLA1. In plasma, 
LPC is produced from phosphatidylcholine present in lipoproteins by the lecithin-cholesterol 
acyltransferase (LCAT). Generated LPLs are subsequently converted to LPA through the 
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activity of a lysophospholipase D named autotaxin (ATX) [116]. This pathway is mainly 
responsible for the synthesis of LPA in different biological fluids such as plasma or serum.  
All above mentioned synthetic pathways are schematically summarized in Figure 6. 
 
Figure 6. LPA metabolic pathways, adapted from[117]. PLA-phospholipase A, PLD-
phospholipase D, LysoPLD-lysophospholipase D, GPAT-glycerol phosphate acyltransferase, 
MAGK-monoacylglcerolkinase, LPP-lipid phosphate phosphatase, LPAAT-LPA-
acyltransferase 
 
2.3 Degradation of LPA 
The half life of circulating LPA is 3 minutes in mice [118]. Such short half-life of the 
phospholipid indicates that it can be either degraded extracellulary or captured by different 
cells and further involved in intracellular metabolic pathways or degraded intracellulary. The 
hydrophobic character of LPA and the lack of specific transmembrane carriers limit the 
possibility of its transmembrane transport. In contrast, LPA can be degraded extracellularly 
through dephosphorylation by a group of enzymes called lipid-phosphate phosphatases 
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(LPPs) that exist under 3 isoforms (LPP1, LPP2, LPP3 and a spliced variant LPP1a) [119] (see 
Figure 6). These enzymes are integral membrane proteins with six transmembrane α-helices 
and three catalytic domains located on the extracellular face of the plasma membrane enabling 
them to dephosphorylate extracellular phospholipids [120]. For example, LPP1 hypomorphic 
mice have increased plasma LPA concentration with longer half-life (12 minutes versus 3 
minutes) compared to control animals indicating that LPP1 is highly involved in the 
degradation of LPA [118]. LPPs can catalyze the dephosphorylation of a variety of other 
phospholipids such as PA, sphingosine-1-phosphate, ceramide-1-phosphate [121]. LPP-
mediated dephosphorylation of bioactive phospholipids limits their bioavailability to activate 
their respective GPCRs thereby reducing their biological effects. LPPs are involved in 
different pathologies, particularly cancer. Indeed, decreased expression of LPP1 and LPP3 was 
described in several cancer types (cancers of lung, breast, ovary) [122]. On the opposite, 
overexpression of LPP1 and LPP3 in ovarian cancer cell lines increases LPA hydrolysis 
therefore inhibiting cell proliferation and colony-forming activity and enhancing apoptosis 
[123, 124]. LPPs are also localized on the internal membranes of endoplasmic reticulum [125] 
and Golgi network [126] with the catalytic domains facing luminal sides of the organelles 
[120] indicating possible regulation of signal transduction processes by dephosphorylation of 
intracellular lipids.  
In intracellular compartment, different enzymes regulate LPA levels. It can be converted to 
PA by the action of acyl-glycerol-3-phosphate acyltransferase (AGPAT) known also as 
LPAAT that catalyzes the transfer of an acyl group from acyl-CoA on LPA [127] (Figure 6). 
LPA can also be deacylated by the action of lysophospholipases [128] (Figure 6).  
One more pathway of LPA degradation was described recently. Dephosphorylation of LPA 
can be catalyzed by the soluble epoxide hydrolase (sEH), an intracellular enzyme with dual 
enzymatic activities: hydrolase at C-terminus and phosphatase at N-terminus of the protein. 
The epoxyeicosatrienoic acid was known as an endogenous substrate of the hydrolase activity 
of sEH and recently it was shown that the phosphatase activity of the enzyme can be 
responsible for the dephosphorylation of different species of LPA [129]. 
The presence of LPA synthetic pathways in both intra- and extracellular compartments rises a 
question: does intracellulary synthesized LPA participate in the formation of extracellular 
pool? It was shown that over-expression of MAGK (an enzyme responsible for intracellular 
synthesis of LPA) in PC3 prostate cancer cells increases LPA production in both intra- and 
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extracellular compartments [111]. Similarly, blockade of 2 isozymes of intracellular synthetic 
enzyme PLA2 (Ca2+-independent PLA2 (iPLA2) and cytosolic PLA2 (cPLA2)) in peritoneal 
mesothelial cells reduces extracellular LPA [130]. These findings suggest that LPA 
synthesized in intracellular space can indeed participate in the formation of extracellular pool 
of LPA. The concept however remains a matter of debates as specific membrane transporters 
required for the transfer of the hydrophobic LPA from intracellular to extracellular space have 
not yet been described.  
 
2.4 Transport of LPA 
Due to its hydrophobic characteristics LPA has to be carried by transport molecules in order 
to be soluble in biological fluids. Albumin and gelsolin are described as transporters of LPA 
in plasma [131, 132]. In addition to their carrier properties these molecules play a role in 
presenting LPA to its receptors and modulating biological effects of LPA. In intracellular 
compartments liver fatty acid binding protein (LFABP) is described as a carrier of LPA [133].  
 
2.5 LPA in biologic fluids 
2.5.1 LPA in blood 
LPA is abundant in serum (up to 10 μM) while its concentration is much lower in plasma 
(about 0.1μM). Part of the difference is attributed to platelet aggregation that occurs during 
serum preparation. Indeed, LPA is produced upon in vitro aggregation of platelets, induced by 
thrombin and/or phospholipase C (PLC) [134] and the action of PLA1 or PLA2 on PA was 
proposed as the synthetic pathway. However, the amount of LPA produced by platelets is not 
high enough to fully account for serum LPA concentration [135]. Moreover, it has been 
proposed that serum LPA would rather originate from hydrolysis, by the circulating ATX, of 
other lysophospholipids (LPC, LPS, and LPE) produced by platelet activation or brought by 
lipoproteins [116, 136]. 
2.5.2 LPA in other biological fluids. 
LPA can be found in other biological fluids such as seminal fluid [137], follicular fluid [138], 
saliva [139], cerebrospinal fluid [140], aqueous humor [141], hen egg white [142], urine 
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[143]. Variation in the amount of LPA in biological fluids is associated with different 
pathologies. Increased LPA was observed in ascitic fluid of patients with ovarian [144] and 
pancreatic cancers [145], synovial fluid of patients with rheumatoid arthritis [146], in vitreous 
fluid of patients with proliferative diabetic retinopathy [147], in cystic fluid of patients with 
autosomal dominant polycystic kidney disease (ADPKD) [148], in cerebrospinal fluid after 
traumatic brain injury [149], in blister fluid [150]. One crucial question is: what are the 
cellular and metabolic origins of LPA in these biological fluids? In seminal, follicular, 
cerebrospinal, blister fluids, urine and hen egg white lysoPLD activity was detected 
suggesting that in these compartments LPA could be produced by ATX. In agreement with 
this, a recent study showed that choline producing activity of follicular fluid is diminished 
when it is incubated with anti-ATX antibodies [151]. However ATX involvement in LPA 
production in various biological fluids requires further confirmation with pharmacological or 
genetic targeting of ATX. Interestingly enzymatic activity responsible for the degradation of 
LPA is described in follicular and seminal fluids indicating that the overall amount of LPA in 
these compartments is the result of a balance between its synthesis and degradation [137, 140, 
142, 151]. In addition to possible local production of LPA in various biological fluids, it can 
theoretically appear in these compartments from circulating plasma pool of the 
lysophospholipid as well. This last notion requires further verification.   
 
2.6 LPA receptors 
LPA is not only an intermediate in lipid/phospholipid metabolism, but is also a bioactive 
ligand of specific receptors through which it can activate different intracellular signaling 
pathways.  
2.6.1 G-protein coupled membrane receptors 
2.6.1.1. Classification and tissue distribution 
LPA receptors are 7-transmembrane domains receptors coupled to G proteins (GPCRs). Six 
receptors (LPA1 to LPA6) coupled to one or more G proteins (Gαi/o, Gαq/11, Gα12/13, Gαs) 
have been described so far.  
Historically LPA1/EDG2 was the first receptor cloned in 1996 and identified as a bona fide 
receptor for LPA [152]. LPA1 receptor is the most widely expressed among different tissues 
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and organs both in mice and humans [153]. During embryonic development LPA1 receptor 
expression is restricted to brain, craniofacial region, limb buds, somites and genital tubercle 
[154]. In postembryonic life highest expression of LPA1 receptors is found in brain and uterus 
but is also present in heart, lung, stomach, kidney, small intestine, testis and some other 
organs [154]. In humans, LPA1 receptor is expressed ubiquitously. 
Following LPA1, 2 more LPA receptors (LPA2/EDG4 and LPA3/EDG7) were identified 
[155, 156]. Expression of LPA2 is more restricted compared to LPA1. It is found in 
embryonic brain but its expression decreases after birth. In adult mouse, high LPA2 
expression is found in kidney, uterus and testis, moderate expression in lung and low 
expression in stomach, spleen and thymus [154]. In human tissues LPA2 expression is more 
restricted, with high expression in testis and leukocytes and moderate expression in prostate, 
spleen, thymus and pancreas [154]. LPA3 is found in murine organs such as lung, kidney, 
uterus, testis, small intestine, heart, stomach, spleen, thymus, whereas it is highly expressed in 
human heart, testis, prostate, pancreas and lesser expression is found in lung, ovary and brain. 
LPA1, LPA2 and LPA3 are members of endothelial differentiation gene (EDG) family to 
which receptors for another bioactive lipid sphingosine-1-phosphate also belong 
(S1P1/EDG1, S1P2/EDG5, S1P3/EDG3, S1P4/EDG6, S1P5/EDG8) [157]. LPA1, LPA2 and 
LPA3 share 50-60% amino acid sequence homology.  
Three additional LPA receptors were also discovered (LPA4/P2Y9 [158], LPA5/GPR92 [159] 
and LPA6/P2Y5 [160]). LPA4 has low expression in mouse and is found in heart, ovary, 
uterus, skin, developing brain and thymus. In humans LPA4 is abundantly expressed in ovary 
[154]. LPA5 is expressed in number of murine tissues, such as small intestine, lung, heart, 
stomach, colon, spleen, thymus, skin and liver. In humans, LPA5 highest expression is found 
in spleen [154]. LPA6 expression is described in hair follicles, kidneys, endothelial cells. 
LPA4, LPA5 and LPA6 receptors are members of the P2Y purinergic family of receptors and 
share nearly 35% of amino acid homology. Three more GPCRs are proposed as new receptors 
for LPA: GPR87 [161], P2Y10 [162] and GPR35 [163]. Nevertheless, further studies are 
required for the validation of these receptors as bona fide receptors for LPA.  
Interestingly for us the most highly expressed receptors in mouse kidneys are LPA2 and 
LPA6 whereas the expression of LPA1, LPA3 and LPA5 is lower [164, 165]. In human 
kidneys only moderate LPA1 expression was described [153]. 
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Figure 7. Gene expression pattern of LPA receptors in human (H) and murine (M) organs 
and tissues. Adapted from [153]. 
 
2.6.1.2 Intracellular signaling pathways 
Activation of LPA receptors induces variety of cellular effects by activating several 
intracellular pathways. LPA1 and LPA2 receptors couple with Gαi/o, Gαq/11, Gα12/13 and 
initiate downstream signaling through molecules such as PLC, diacyglycerol (DAG), 
mitogen-activated protein kinase (MAPK), protein kinase B (Akt), phosphatidylinositol 3-
kinase (PI3k) and Rho family of GTPases. Activation of these receptors promotes cell 
proliferation, survival and migration and cytoskeletal changes [166, 167]. LPA3 couples with 
Gαi/o, Gαq/11 and mediates LPA-induced Ca2+ mobilization, adenylyl-cyclase inhibition, 
phospholipase C and MAPK activation [167]. LPA4 couples to Gαi/o, Gαq/11, Gα12/13, Gαs and 
induces stress fiber formation and neurite retraction through Gα12/13 and downstream 
Rho/ROCK pathway [158, 168]. LPA4 is the only LPA receptor that couples to Gαs and leads 
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to intracellular cAMP accumulation upon activation. LPA5 couples to Gα12/13 and induces 
stress fiber formation and neurite retraction. It couples also to Gαq/11 and increases 
intracellular Ca2+ [159]. LPA6 receptor couples to G13-Rho signaling pathway and induces 
Rho-dependent alteration of cellular morphology [169].  
 
Figure 8. LPA receptor signaling pathways, adapted from[154] 
 
2.6.1.3 Relative specificity of LPA receptors towards different LPA species 
Composition of different LPA species was described in plasma. In healthy individuals the 
unsaturated 18:2, 18:1 and 20:4 constitute the majority of LPA species [170]. Increased LPA 
levels were detected in plasma of patients with ovarian or other gynecological cancers, 
moreover unsaturated fatty acid species of plasma LPA were associated with late stage and 
recurrent cancers [171, 172]. In parallel, LPA is present in ascitic fluid of patients with 
ovarian cancer where the majority of LPA species has saturated fatty acid chains [144]. 
Interestingly for us composition of LPA molecular species was measured in the urine of rats 
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with unilateral ureteral obstruction (UUO). In the urine from non-obstructed kidneys the 
major constitute is 16:0 followed by 18:1, whereas in urine from obstructed kidneys saturated 
species (16:0 and 18:0) are predominant [173]. LPA molecular species in plasma of UUO rats 
doesn’t differ from that of control animals with predominant poly-unsaturated 18:2 and 20:4 
species [173]. These discrepancies in LPA molecular composition between plasma and other 
biological compartments in physiological and pathological states can be due to different 
metabolic sources in these biological fluids. It can indicate also varying biological roles of 
different LPA molecular species in pathological settings. This is in agreement with previous 
studies indicating that LPA species with unsaturated fatty acids (18:1 and 18:2) are more 
potent than species with saturated fatty acids (16:0 and 18:0) in growth stimulation and 
induction of intracellular Ca2+ in ovarian cancer cells [144]. Other studies showed the rank 
order potency for different LPA species in various biological activities. For example, for the 
stimulation of deoxyglucose transport in Xenopus oocytes the rank order potency of LPAs 
with different acyl groups in the sn-1 position was LPA18:1 > LPA16:0 > PA = LPA18:0 > 
LPA12:0 [174]. One more example was the rank order potency of different LPA species to 
induce Ca2+ mobilization in human A431 carcinoma cell line: LPA18:1 > LPA20:4 > 
LPA18:3 > LPA18:2 > LPA18:0 = LPA16:0 > LPA12:0 [175].  In addition, different LPA 
receptors show varying levels of preference towards various LPA species. While LPA1 and 
LPA2 do not discriminate between saturated and unsaturated LPA species, LPA3 is 
preferentially activated by unsaturated LPA [156]. LPA4 receptor prefers monounsaturated 
LPA species with 18 carbon atoms whereas the potency for other species is lower [158]. 
LPA5 shows 10-fold preference for alkyl-18:1 LPA compared to acyl-18:1 LPA [176]. LPA6 
receptor prefers 2-acyl-LPA species and requires much higher LPA concentrations to show an 
effect compared to LPA1-LPA5 [169]. Despite the varying affinities of the LPA receptors 
towards different LPA species, and differencies in the potency of various LPA species in 
inducing a biological effect, LPA18:1 remains the most commonly used molecule in 
biological research. Therefore it could be interesting to propose the usage of a mix of LPA 
species, composition of which could simulate the LPA molecular composition in 
physiological or pathological conditions.  
2.6.1.4 Genetic deletions and associated pathologies 
The use of gene silencing techniques and pharmacological targeting of different receptors 
helped to understand the physiological roles of each LPA receptors and their possible 
involvement in physiopathology (see Table 4).   
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Receptor Phenotype of KO animal Involvement in pathologies 
LPA1 
50% perinatal lethality due to defective 
olfaction and impaired suckling, 
decreased survival, reduced body size, 
frontal cerebral hematomas and 
craniofacial dysmorphism [177], defects 
in neurodevelopment [178-180] 
Neuropathic pain, spatial memory 
impairments, schizophrenia [181] 
Fibrotic diseases [164, 182] 
Cancers [183] 
Obesity [184] 
Rheumatoid arthritis [185] 
Male infertility [186] 
LPA2 
No abnormal phenotype described [187] 
LPA1 and LPA2 double knockout mice 
show no additional phenotypic 
alterations compared to LPA1 knockout 
animals, except higher rates of perinatal 
frontal hematomas 
Cancers [188, 189] 
Asthma [190, 191] 
Male infertility [186] 
LPA3 
Animals are grossly normal at birth and 
viable but female mice have striking 
phenotype in reproductive system 
Delayed embryo implantation and 
altered embryo spacing, embryo 
crowding and reduced litter size 
[192, 193] 
Male infertility [186] 
LPA4 
Decreased gestational survival and 
altered angiogenesis [194] 
Increased tubular bone volume and 
thickness [195] 
Cell motility[196] 
LPA5 No described abnormal phenotype [197] 
Neuropathic pain[197] 
 
LPA6 
No information available about KO 
animals 
Hair loss [160, 198] 
Development of bladder cancer [199] 
 
Table 4. The phenotypic characteristics of LPA receptor KO animals and involvement of LPA 
receptors in pathologies. 
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Some LPA receptors have crucial role during embryonic development. LPA1 receptor 
signaling is very important for the normal development of nervous system and LPA1 
deficiency causes anatomical alterations of the brain as well as neurochemical changes similar 
to different psychiatric disorders (schizophrenia, depression). LPA1 signaling is implicated in 
various pathologies such as kidney and lung fibrosis, neoplastic diseases, obesity etc. [164, 
182-184]. While LPA2 receptor deficiency doesn’t cause detectable phenotypical changes, its 
activation plays a role in bronchial asthma and cancers of breast, colon and ovary [188, 189, 
191, 200]. The most important phenotypic change observed in LPA3 deficient animals 
concerns the embryo implantation [192, 193]. Animals lacking LPA4 receptors have high 
embryonic lethality and demonstrate aberrant angiogenesis with hemorrhages, edema and 
dilated blood and lymph vessels [194]. Phenotype of LPA4-/- mice resembles that of animals 
invalidated for ATX gene [201] indicating possible involvement of LPA4 receptors in ATX-
induced effects during embryonic development. Surviving LPA4-/- mice show increased 
osteogenesis [195]. LPA5 deficient animals have normal phenotype and are protected from 
neuropathic pain [197]. While LPA6 knockout animals have not described so far, a mutation 
of LPA6 has been reported in genetic forms of hair loss [160, 198]. Interestingly a mutation in 
a gene encoding PA-PLA1α (LIPH), an enzyme involved in LPA synthesis, also leads to the 
development of hypotrichosis [202, 203]. It was proposed that PA-PLA1α-LPA-LPA6 axis 
regulates differentiation and maturation of hair follicles through LPA-induced EGFR 
transactivation [204].  
Interesting for us, LPA receptor deletions showed that loss of basal expression of none of the 
LPA receptors causes altered kidney structure or function. Nevertheless LPA signaling 
through certain LPA receptors is involved in the pathogenesis of kidney pathology (discussed 
later).    
2.6.2 Intracellular receptors 
PPARs are transcription factors of the nuclear receptor superfamily that heterodimerize with 
retinoic acid X receptor upon binding with agonists and regulate gene expression by binding 
to specific response elements in promoter regions that are known as peroxisome proliferator 
response elements (PPRE). Three isoforms of PPARs, PPAR-alpha (PPARα), PPAR-
beta/delta (PPARβ/δ) and PPAR-gamma (PPARγ) have been described so far [205]. PPARγ 
was identified as intracellular receptor for LPA since it competes with the classical PPARγ 
agonist rosiglitasone on purified PPARγ protein. It also increases the transcription of cells 
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transfected with PPRE reporter gene. Activation of PPARγ by LPA stimulates also the 
expression of CD36 and promotes cholesterol uptake by human monocytes forming foam 
cells, leads to neointima formation and dedifferentiation of vascular smooth muscle cells 
[206, 207]. These effects are however limited to unsaturated and alkyl-ether forms of the 
LPA. In addition it was shown that only intracellular LPA synthesized by GPAT is able to 
activate PPARγ [208]. Moreover, it was shown that extracellular LPA is not able to activate 
PPARγ in 3T3F442A adipocyte cells [184]. The indirect activation of PPARγ as the 
consequence of intracellular pathways activated by membrane LPA receptors has also been 
reported [209]. These contradictory observations could indicate that LPA activation of PPARγ 
is cell-type specific and depends on chemical composition of the LPA molecule.  
2.6.3 Other potential receptors 
It was shown that LPA-induced pain-like behavior is at least partially attributed to the direct 
activation of transient receptor potential vanilloid 1 (TRPV1) ion channel through binding to 
its C-terminal [210].  
Another potential LPA receptor is RAGE (receptor for advanced glycation end products) that 
is a transmembrane receptor of immunoglobulin superfamily and that was shown to be 
required for LPA-mediated proliferation and migration of vascular smooth muscle cells as 
well as for LPA-induced ovarian tumor implantation and metastasis [211].  
2.6.4 LPA receptor antagonists 
Most antagonists target LPA1 and/or LPA3 receptors with different levels of selectivity. The 
pharmacological characteristics of some LPA receptor blockers are discussed here.  
Ki16425 [3-(4-[4-([1-(2-chlorophenyl)ethoxy]carbonyl amino)-3-methyl-5-isoxazolyl]:This is 
a non-lipid antagonistthat has been synthesized by Kirin Brewery Co [212] and that is 
commercially available from Cayman Chemicals. This is the most extensively used LPA 
receptor antagonist in biological research. It is an LPA1 and LPA3 receptor antagonist 
without clear subtype preference [212]. Ki16425 is commonly used to demonstrate the 
receptor-dependence of a cell response (proliferation, migration, calcium mobilization) 
activated by LPA [213, 214]. Ki16425 is able to inhibit the constitutive activity of LPA 
receptors reinforcing the blocking activity of this molecule towards LPA [215]. It is 
noticeable that Ki16425 was reported to exert a partial PPARγ agonist activity indicating that 
some effects of the molecule could be explained by LPA receptor independent actions [216]. 
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VPC12249 ((S)-phosphoric acid mono-[3-(4-benzyloxyphenyl)-2-octadec-9-enoylamino-
propyl] ester): It is a lipid antagonist and is commercially available from Avanti Polar Lipids. 
VPC12249 behaves as a LPA1 and LPA3 receptor antagonist without clear subtype 
preference [217]. In vitro experiments showed that it inhibits migration of pancreatic cancer 
cells induced by malignant ascitic fluid [145], blocks LPA-induced increase of intracellular 
Ca2+ in skeletal muscle cells of C2C12 cell line and attenuates osteoclast differentiation [218, 
219]. 
Efficiency of these two molecules has been tested in several in vivo experiments as well (see 
2.7). The poor water solubility of both of them was the major limiting factor for their use in 
clinical trials.  
AM966 ( (4'-[220]-biphenyl-4-yl)-acetic acid) and AM095 ((sodium, {4'-[3-methyl-4-((R)-1-
phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-acetate)): AM966 and AM095 
are non-lipid antagonists synthesized by Amira Pharmaceuticals and both exhibit higher 
LPA1 receptor selectivity when compared to LPA3 subtype as assessed by the ability to 
induce calcium release or GTPγS binding in CHO cells expressing LPA receptors [220, 221]. 
These are the only available LPA receptor antagonists that can be administered orally with 
good pharmacokinetic profile.   
 
2.7 Physiological and pathophysiological effects of LPA 
2.7.1 Cancer 
The role of LPA in human pathologies has been extensively studied in cancer. LPA has been 
implicated in initiation and progression of different cancer types, such as ovarian, breast, 
prostate, colon, thyroid cancers etc. It was shown that ascitic fluid and plasma of patients with 
ovarian cancer contain elevated amounts of LPA that is responsible for growth and 
proliferation of ovarian cancer cells in vivo and in vitro [144, 172, 222-224]. Besides 
promoting proliferation LPA also leads to increased survival of cancer cells through inhibition 
of apoptosis [225], reduces sensitivity to chemotherapy [226], promotes migration [227], 
induces angiogenesis [228, 229] and enhances invasiveness and metastatic potency of cancer 
cells through secretion of uPA and activation of MMPs [230-232]. Expression of enzymes 
involved in LPA metabolism is changed in different types of cancers: increased ATX 
expression is found in Hodgkin lymphoma, glioblastoma, hepatocellular carcinoma, renal-cell 
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carcinoma, breast cancer, non-small-cell lung cancer [233], whereas expression of LPPs 
(LPP1 and LPP3) is decreased in breast, ovarian and lung cancers [122]. In addition LPA 
receptor expression is also changed in certain cancer types: LPA2 expression is increased in 
ovarian, colorectal and thyroid cancers [234-236], and LPA1, LPA2, LPA3 in breast cancer 
cells [237]. Treatment with LPA1/3 receptors antagonist Ki16425 attenuates formation of 
bone metastasis in xenograft model of breast cancer [183]. Changes in expression of 
metabolic enzymes leading to increased LPA availability in parallel with increased expression 
of LPA receptors are the prerequisites for the increased LPA signaling and protumorigenic 
action. Analyzing all these data it can be concluded that LPA can be a tumor biomarker for 
certain types of tumors and represents also an interesting target for the development of 
potential antitumoral chemotherapeutic agents.   
2.7.2 Reproductive system  
LPA signaling is implicated in different aspects of reproduction such as ovarian function, 
spermatogenesis, fertilization, embryo implantation and spacing, pregnancy maintenance, 
parturition etc. LPA is present in follicular fluid and is supposed to be produced by the ATX 
activity [138]. In vitro experiments showed that LPA promotes oocyte maturation suggesting 
that LPA in follicular fluid could be responsible for oocyte growth and maturation in vivo 
[238]. LPA also stimulates mouse ovum transport by contracting smooth muscle cells of 
oviduct [239] and plays a role in fertilization by inducing acrosomal reaction [240]. LPA-
LPA3 signaling in the uterus is important in early pregnancy as LPA3 deficient animals 
showed uneven embryo spacing and embryo crowding, delayed embryo implantation and 
prolonged pregnancy. Decreased prostaglandin production is at least partially responsible for 
the LPA3 deficient female mice phenotype [192, 193]. LPA2 and LPA3 receptors are 
upregulated in placental tissue of patients with gestational hypertensia and pre-eclampsia 
[241]. These disorders worsen with the progression of pregnancy and are associated with a 
parallel increase in LPA levels suggesting the involvement of LPA signaling in these 
hypertensive pathologies [242]. In addition LPA signaling could be implicated in the initiation 
of labor since it contracts uterine smooth muscle cells in vitro and increases intrauterine 
pressure in vivo similar to PGF2α [243]. 
2.7.3 Cardiovascular system 
LPA is involved in different aspects of cardiovascular physiology and pathophysiology. First 
of all it plays a role in different steps of atherosclerosis. LPA is found in lipid-rich core of 
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atherosclerotic plaques where it is produced through the action of ATX on LPC during 
oxidation of low-density lipoproteins (LDL) [244]. LPA promotes endothelial chemokine 
secretion (CXCL1, IL8, MCP-1) and increases expression of adhesion factors (ICAM-1, 
VCAM-1, E-selectin) leading to recruitment of monocytes into atherosclerotic lesion. These 
effects are mediated through LPA1 or LPA3 receptors [245-248]. LPA mediates the effects of 
minimally modified LDL on monocyte activation via LPA1 receptor [249]. It also increases 
uptake of oxidized LDL in macrophages by increasing scavenger receptor A and induces 
foam cell formation through LPA1 and LPA3 receptors and PPARγ [206, 250]. LPA induces 
platelet adhesion and thrombus formation via the alteration of platelet shape, fibronectin 
deposition and matrix formation, platelet-monocyte interaction [251-254]. LPA is partially 
responsible of platelet activation induced by mildly oxidized LDL [244, 255, 256] and would 
thus be involved in thrombus formation upon rupture or erosion of atherosclerotic plaque 
during myocardial infarction or ischemic stroke. LPA is also implicated in neointima 
formation by inducing proliferation and migration of vascular smooth muscle cells [257-260] 
as well as by recruiting smooth muscle progenitor cells through LPA1 and LPA3 mediated 
activation of CXCL12 [261].  
2.7.4 Inflammatory diseases 
Different studies showed that LPA can exert anti-inflammatory activities. Treatment with 
LPA (18:1 or 18:0) increases animal survival upon LPS-induced sepsis, attenuates damage to 
liver and neuromuscular junction, reduces plasma levels of IL1β and TNFα and decreases 
myeloperoxidase activity in lungs [262, 263]. Protective effects of LPA18:1 were blocked 
with both LPA1/3 antagonist (Ki16425) and a PPARγ antagonist (GW9662) whereas the 
effects of LPA18:0 were blocked with only Ki16425 [263]. These data suggest that the 
mechanism of protective effect of LPA could be related to acyl chain saturation with LPA18:0 
acting via GPCRs and LPA18:1 acting via GPCRs and PPARγ. Interestingly a recent study 
found increased LPA and decrease LPC plasma levels upon peritoneal sepsis induced by cecal 
ligation and puncture [264]. In parallel plasma ATX activity was reduced suggesting that 
increased production of LPA in plasma was not mediated through ATX action. Metabolic 
sources of increased LPA upon sepsis remain unknown.  
On the opposite LPA can exert pro-inflammatory properties. In air pouch model of 
inflammation, LPA leads to LPA1 and LPA3 receptor dependent and CXCR2 mediated 
leukocyte recruitment and release of pro-inflammatory cytokines [265].  It was shown that 
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ATX and LPA levels increase in bronchoalveolar lavage fluid in patients with allergic asthma 
[190]. In mouse model of allergic asthma, ATX blockade or LPA2 receptor knockout reduces 
allergic lung inflammation [190, 191]. LPA and ATX are also increased in synovial fluid of 
patients with rheumatoid arthritis. LPA stimulates cycloxygenase-2 (COX-2) induction and 
prostaglandin E2 synthesis in synovial fibroblasts via abundantly expressed in synovial tissue 
LPA1 receptors whereas abrogation of LPA1 signaling reduces cellular infiltration and bone 
destruction in mouse model of rheumatoid arthritis [146, 185].  
The apparent contradictory effects of LPA in inflammatory processes can be explained by 
different type and activity state of immune cells as well as by the differences of LPA 
receptors expressed in immune cells in the different pathological contexts [266].  
2.7.5 Obesity 
Adipose tissue produces LPA that promotes proliferation of preadipocytes [267]. Secreted 
ATX is mostly responsible for this LPA production and the expression of ATX is higher in 
differentiated adipocytes compared to preadipocytes [268, 269]. Adipocyte-specific deletion 
of ATX leads to 40% reduction in plasma LPA demonstrating contribution of adipose tissue 
in the overall production of LPA in the body [270]. Increased ATX expression is found in 
adipose tissue of genetically obese diabetic db/db mice and in visceral adipose tissue of obese 
patients with glucose intolerance [271, 272]. LPA-induced preadipocyte proliferation is 
LPA1-dependent [273]. At the same time LPA inhibits preadipocyte differentiation and 
adipogenesis via LPA1-dependant down-regulation of pro-adipogenic factor PPARγ [184]. In 
addition LPA alters glucose homeostasis in the body by decreasing glucose-induced insulin 
secretion and possibly by promoting adipose tissue fibrosis [274, 275]. LPA-induced fibrosis 
of adipose tissue is blocked by the LPA1/3 antagonist Ki16425 [275].   
2.7.6 Nervous system 
 LPA is found in cerebrospinal fluid as well as in different regions of central nervous system 
and its local production increases in multiple sclerosis and nerve injury [276, 277] indicating 
its role in normal functioning and pathologies of central nervous system. LPA is highly 
involved in normal brain development through LPA1 receptors deletion of which causes 
striking features (see table 4). In addition LPA1 receptor deficient animals demonstrated 
behavioral changes as well as neurochemical alterations that are characteristic of 
schizophrenia, depression, anxiety, bipolar psychosis [278]. LPA injection into developing 
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brains leads to hydrocephalus formation that is prevented with genetic invalidation or 
pharmacologic blockade of LPA1 receptors [279].  
ATX expression is increased in frontal cortex of patients with Alzheimer’s disease [280] and 
LPA increases tau phosphorylation and Aβ production in neurons [281, 282]. Therefore, the 
LPA/ATX axis appears as a potential interesting target for the development of treatment 
strategies for Alzheimer’s disease. LPA also initiates neuropathic pain and peripheral nerve 
demyelination through LPA1 receptor mediated Rho-ROCK activation [283, 284] or through 
the interaction with TRPV1 channels [210]. Injection of Ki16425 attenuates pain-like 
behavior in mice [285].   
2.7.7 Wound healing and fibrotic diseases 
Whereas wound healing after injury is considered as physiologic process with eventual 
restoration of the tissue function, aberrant wound healing due to chronic injury and sustained 
production of pro-fibrotic mediators leads to excessive accumulation of ECM and the 
eventual development of fibrosis. Development of fibrosis leads to altered architecture of the 
tissue with further loss of function. Depending on tissue context, LPA can either favor wound 
healing or be a pro-fibrotic factor.  
2.7.7.1 Wound healing: Multiple studies involve LPA in wound healing and scar formation of 
different tissues such as skin, intestine and cornea [286-288]. LPA promotes growth of 
epithelial cells from tongue, pharynx and esophagus and it thus was proposed that LPA 
present in saliva can be involved in the healing of wounds of upper gastrointestinal tract 
[139].  
2.7.7.2 Pulmonary fibrosis: LPA level is elevated in bronchoalveolar lavage (BAL) fluid of 
mice with bleomycine- and radiation-induced pulmonary fibrosis and in patients with 
idiopathic pulmonary fibrosis [182, 289]. LPA promotes pulmonary fibrosis by inducing 
vascular leakage and fibroblast recruitment. Genetic deletion of LPA1 receptors as well as 
pharmacologic blockade with the LPA1 specific antagonists AM095 or AM966 or with the 
LPA1/LPA3 receptor antagonists VPC12249 or Ki16425 reduces collagen deposition and 
fibroblast accumulation, decreases expression of TGF-β1, α-SMA, CTGF and protects against 
lung fibrosis in animal models of the disease [182, 220, 221, 289, 290]. Fibroblasts obtained 
from patients with idiopathic pulmonary fibrosis show high expression of LPA1 receptors and 
BAL fluid from same patients induces chemotaxis of human lung fibroblast that was blocked 
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with Ki16425 [182]. ATX level is increased in BAL fluid from bleomycin induced pulmonary 
fibrosis and specific deletion of ATX from epithelial cells and macrophages as well as 
pharmacologic inhibition of ATX attenuates fibrotic events in lungs [291]. Thus, LPA1 
receptor and ATX are identified as targets for the treatment of pulmonary fibrosis and two 
molecules, the LPA1 antagonist BMS-986020 (NCT01766817) and the ATX inhibitor 
GLPG1690 (NCT02738801), entered phase IIa clinical trials to test their efficacy in patients 
with idiopathic pulmonary fibrosis.   
2.7.7.3 Hepatic fibrosis: Patients with chronic hepatitis C and animals with chemically 
induced liver fibrosis have higher plasma LPA levels and increased serum ATX activity. Both 
parameters correlate with histological stage of fibrosis and blood markers of liver injury [292, 
293].  Involvement of LPA in the pathogenesis of hepatic fibrosis was further reinforced by in 
vitro studies showing that LPA promotes migration of hepatic myofibroblasts[294], leads to 
proliferation of stellate cells and increases their contractility [295, 296]. Moreover, a recent 
study showed that inhibition of ATX activity in mice reduces liver fibrosis [297]. 
2.7.7.4 Systemic sclerosis: Patients with systemic sclerosis have increased LPA levels in 
plasma [242]. Activated platelets play an important role during the pathogenesis of this 
disease and are proposed as the major source of circulating LPA in these patients. 
Pharmacological blockade of LPA receptors with LPA1/3 antagonist Ki16425 or with the 
LPA1 selective antagonist AM095, and the genetic deletion of LPA1 receptors attenuated 
dermal fibrosis in a bleomycin-induced murine model of systemic sclerosis [290, 298]. LPA1 
receptor was proposed as an efficient target for the treatment of systemic sclerosis and the 
LPA1 antagonist SAR100842 (NCT01651143) entered phase IIa clinical trial to test the drug 
efficacy in patients.  
2.7.7.5 Kidney fibrosis.The involvement of LPA in kidney fibrosis is discussed thoroughly in 
2.8.  
 
2.8 LPA in kidney pathology 
The first report of a change in LPA production associated with kidney disease was made by a 
japanese group that found increased plasma LPA concentration in 18 patients with renal 
failure on hemodialysis compared to healthy individualswhile no difference was observed 
before and after dialysis [299]. Because the cellulose membranes used for hemodialysis were 
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known to activate platelets [300], the authors concluded that platelet aggregation could 
explain the increase in plasma LPA. Later, metabolomic analysis of serum from patients 
with CKD showed elevated concentrations of two molecular LPA species (LPA16:0 and 
LPA18:2) that, in combination with 5 other metabolites, were proposed as useful 
biomarkers for the discrimination of CKD patients from healthy subjects [301]. In 
addition it has been demonstrated that serum ATX level was independently associated with 
proteinuria and kidney lesions in patients with biopsy-proven diabetic nephropathy [302]. 
Since LPA receptors are expressed in kidneys and since kidney possesses the required 
metabolic machinery to produce LPA [164, 173], kidney is a likely target of LPA. Whether 
increased serum LPA in patients with kidney diseases is the consequence and/or the cause in 
the pathogenesis of these pathologies is an open question that experimental approaches in 
animal models might help to answer.  
2.8.1 LPA and renal obstruction 
Unilateral ureteral obstruction (UUO) in rodents is a well-established experimental model that 
results in rapid development of TIF in the obstructed kidney. Ureter is ligated at the uretero-
pelvic junction after abdominal incision of anesthetized animal. Renal blood flow and 
glomerular filtration rate are reduced within 24 hours and are followed by hydronephrosis, 
interstitial inflammation and tubular epithelial cell death due to apoptosis or necrosis within 
the next few days. Subsequent proliferation of interstitial fibroblasts and the phenotypic 
transformation of resident renal cells into myofibroblasts with further deposition of ECM 
proteins lead to eventual TIF [303]. In 2007, our group has shown in UUO mice that in vitro 
release of LPA by explants from obstructed kidneys was nearly 3 fold higher than those 
prepared from intact kidneys [164]. In UUO rats, it was reported that the concentration of 
LPA in the urine that accumulates in obstructed kidney was higher (about 3 fold) than in urine 
collected in bladder [173]. These reports indicate that renal LPA production is increased in 
obstructed kidneys. Increased ATX and AGK expression in combination with increased 
choline producing activity in obstructed kidneys was demonstrated as well [173] suggesting 
that these enzymes are possibly responsible for the increased LPA production from obstructed 
kidneys. However, the hypothesis remains to be verified through the use of pharmacological 
tools or genetic ablation of above mentioned enzymes.  
What could be the consequences of increased renal production of LPA? UUO is associated 
with increased renal expression of LPA1 receptor [164, 165]. On the opposite, genetic 
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invalidation of LPA1 or pharmacological blockade of LPA receptors with the LPA1/LPA3 
antagonist Ki16425 or the LPA1 specific antagonist AM095 block the development of TIF, 
decreased the renal expression of CTGF and TGFβ, reduced the amount of proliferating 
fibroblasts and the accumulation of αSMA positive myofibroblasts associated with UUO 
[164, 165, 221]. These observations showed that the LPA-LPA1 signaling axis plays an 
important role in the process of TIF that develops in obstructed kidney. 
Epithelial cells of proximal tubules in obstructed kidneys are responsible for the majority of 
increased CTGF expression after obstruction [165]. In mouse primary tubular epithelial cells 
all subtypes of LPA receptors are present with LPA2 being the most abundant, followed by 
LPA1 whereas in human primary tubular epithelial cells high expression of LPA2 and traces 
of LPA1 are shown [165, 304]. In addition, previous experiments demonstrated that proximal 
tubular epithelial cells are sensitive to LPA, as it induces Ca2+ mobilization in these cells, 
inhibits serum deprivation-induced apoptosis and promotes proliferation of these cells through 
activation of PI3K or ERK pathways [305-307]. Therefore, LPA-induced increased CTGF 
expression in obstructed kidney could result from the action of increased LPA on tubular 
cells. This hypothesis was confirmed by in vitro experiments which demonstrated that LPA1 
receptor activation induces CTGF and TGFβ expression via a Gα12/13-Rho/ROCK pathway 
with downstream actin polymerization and induction of myocardin-related transcription factor 
(MRTF) - serum response factor (SFR) pathway [164, 165]. Another source of CTGF in 
kidney is resident fibroblasts and LPA was shown to induce CTGF production in cultured 
renal fibroblasts as well through activation of small GTPase RhoA [308]. It was also shown 
that LPA2 receptor can mediate LPA-induced CTGF expression in tubular cells. LPA2 
receptor knockdown results in diminution of LPA-induced CTGF expression [165]. 
Moreover, LPA signaling through LPA2 receptors and Gαq proteins in cultured proximal 
tubular cells transactivates latent TGFβ in Rho/Rho-kinase and αvβ6 integrin dependent 
manner. Activated TGFβ then induces CTGF and PDGF secretion [309]. Involvement of 
LPA-LPA2 axis in the development of kidney fibrosis needs however in vivo confirmation. If 
it is proven, LPA2 receptors in parallel with LPA1 receptors can represent interesting targets 
for the development of therapeutic strategies against kidney fibrosis. 
2.8.2 LPA and diabetic nephropathy 
Diabetic nephropathy (DN) was reported to be associated with the accumulation of 
lysophospholipids in kidney. Increased choline uptake and phosphorylation as well as LPC 
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accumulation were demonstrated in mice with sterptozotocin-induced diabetic nephropathy 
that was attenuated with insulin therapy [310]. MALDI/MS imaging revealed an increased 
production of LPC and LPA in glomerular areas of db/db diabetic mouse kidneys expressing 
clear symptoms of nephropathy. Treatment of animals with an inhibitor of oxidative processes 
diminishes both symptoms of nephropathy and renal accumulation of the lysophospholipids 
without impacting blood glucose levels [311]. These observations are in agreement with other 
reports indicating that DN is associated with increased expression of several phospholipases 
involved in LPC and LPA synthesis in kidneys of diabetic animals [268, 312, 313] and in 
mesangial cells exposed to high glucose in vitro [313-315]. These observations have some 
clinical relevance since it was shown that serum ATX level is independently associated with 
proteinuria and kidney lesions in patients with DN [302]. Moreover, recent data from our 
group show that patients with diabetic nephropathy have higher concentrations of LPA and 
LPC in their urine compared to diabetic patients without nephropathy [316]. 
Mesangial cells not only produce lysophospholipids [311] but also express LPA receptors 
[317] and are sensitive to LPA. It acts as a survival factor for cultured rat mesangial cells and 
promotes their proliferation through activation of MAPK and can be synergistic to the 
proliferative effect of PDGF [318-320]. In parallel, LPA induces mesangial cell contraction in 
vitro by mobilization of intracellular Ca2+ through activation of phosphoinositide cascade and 
by favoring Ca2+ entry across the plasma membrane [321]. In human or rat mesangial cells 
LPA induces CTGF, a pathway that could play a role in the development of 
glomerulosclerosis [322, 323]. Since mesangial proliferation, contraction and 
glomerulosclerosis are hallmarks of DN, LPA could play a role in DN pathogenesis by acting 
on mesangial cells. The hypothesis is supported by a very recent study showing that 
albuminuria, ECM deposition in glomerules and TGFβ expression in kidneys of diabetic mice 
were reduced in animals treated with the LPA receptor antagonist Ki16425 [324]. The same 
report shows that treatment of cultured mouse mesangial cells with Ki16425 as well as 
genetic knockdown of LPA1 receptors reduces LPA-induced TGFβ expression [324]. Even 
though glomerules are the initially affected kidney structures during DN, diabetic 
microangiopathy causes reduced postglomerular blood flow to peritubular capillaries and, 
consequently TIF develops in parallel to disease progression. As a result, the whole nephron 
is damaged in later stages of the disease. Since LPA-LPA1 axis was shown to be responsible 
for the development of both glomerulosclerois and TIF, it could be an interesting target for 
the treatment of DN.  
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RAGE signaling is an important component for the development of DN since overexpression 
of RAGE in endothelial cells of diabetic mice leads to enhanced glomerular hyperthrophy, 
measngial expansion and glomerulosclerosis, increased serum creatinine and albuminuria 
compared to diabetic controls [325]. In contrast, deletion of RAGE in diabetic mice or 
treatment with soluble RAGE attenuates albuminuria and improves diminished kidney 
function, mitigates mesangial expansion, glomerulosclerosis and thickening of GBM [326].  
Since RAGE is known as a potential receptor for LPA, one could ask whether LPA-induced 
kidney fibrosis in DN could be mediated by activation of RAGE.  
2.8.3 LPA and other CKDs 
Autosomal dominant polycystic kidney disease (ADPKD) is the most common form of 
inherited renal cystic diseases characterized by bilateral renal cysts, various extrarenal 
manifestations and development of ESRD in 50% of patients in the 4th to 6th decade of life 
[327]. The epithelial cell line mpkCCDcl4 exhibits major characteristics of distal tubular 
epithelial cells that cover the majority of cysts in ADPKD. It was shown that LPA is a 
bioactive component of cystic fluid of patients with ADPKD able to induce cystic fibrosis 
transmembrane conductance regulator (CFTR)-mediated Cl- secretion in mpkCCDcl4 cells 
[148]. LPA-induced Cl- secretion is due to activation of LPA receptors from the basolateral 
side of cells and could be responsible for the expansion of cysts with future diminution of 
kidney function in these patients [148].  
Human immunodeficiency virus (HIV)-associated nephropathy, is characterized by collapsing 
focal segmental glomerulosclerosis, microcystic tubular dilatation and interstitial 
inflammation with progressive renal failure, often accompanied by proteinuria [328]. In a 
more recent study it was shown that, in human proximal tubular epithelial cells, HIV was able 
to promote secretion of profibrotic proteins and EMT through activation of different 
subcellular pathways (FAK/ILK-PI3K-NFκB cascade). LPA plays a critical role in HIV-
induced changes that were blocked by either LPA receptor blocker or inhibitors of LPA 
synthesis [329]. 
Complementary studies are now required to better understand the role of LPA in both 
ADPKD an HIV-associated nephropathy.   
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2.8.4 LPA and acute kidney injury  
In contrast to all above-mentioned data where LPA was involved in the development of 
kidney diseases as a causative factor, it was also found that LPA can exert some protective 
effects in acute kidney injury (AKI). Especially it was shown that in vivo injection of 
LPA18:1 to mice reduces ischemia/reperfusion (I/R)-induced increase in plasma creatinine 
and BUN showing protection against I/R-induced kidney dysfunction [330, 331]. The 
protection was accompanied by a reduction of caspase dependent apoptosis, inflammation and 
neutrophil influx into kidney tissue, by an inhibition of the complement activation, reduction 
in brush border destruction, epithelial edema and number of intraluminal casts [330, 331]. In 
another study it was shown that low doses of exogenous LPA18:1 perform protection in I/R-
induced AKI which was lost with increasing doses of LPA [332]. In opposite to protective 
effect, AKI was exacerbated when LPA treatment was substituted with LPA3 receptor agonist 
OMPT. Moreover, LPA1/3 receptor antagonist VPC-12249 by its own reduces leukocyte 
infiltration and inflammation and protects against I/R-induced AKI. That VPC-12249-induced 
protection was lost when treatment with VPC-12249 was combined with OMPT [332]. The 
authors concluded that signaling through LPA3 receptors induces deleterious effects during 
AKI whereas signaling through other receptors exerts protective effects. Since LPA2 
receptors are highly expressed in kidney, the authors conclude that signaling through LPA2 
might be responsible for the LPA-induced protection upon I/R-induced AKI. However, 
relatively low expression of LPA1 receptors couldn’t exclude its involvement in LPA-induced 
protection. Moreover, at the period of that study other LPA receptors (LPA4-LPA6) were not 
described and possible protection by signaling through these receptors should also be 
considered. In addition, TRPV1 activation by specific agonists was reported to protect kidney 
during I/R [333, 334]. Since TRPV1 is a potential receptor for LPA, kidney protection 
induced by LPA could be mediated by TRPV1 activation as well. The affinity of LPA3 
receptor is lower for LPA18:1 compared with other receptors. At low doses LPA18:1 
activates possible "protective receptors", exerting some protection. High doses of LPA18:1 
overcome the low affinity of LPA3 receptors resulting in the loss of protection. Interestingly 
treatment with OMPT, VPC-12249 or combination of both compounds did not modified heart 
rate or blood pressure indicating that the effects exerted by these molecules could not result 
from hemodynamic changes [332]. Even though VPC-12249 exerts protection upon AKI, it is 
not known whether it acts directly on tubular cells or exerts anti-inflammatory effects acting 
on inflammatory cells.  
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The discrepancy of results in these experiments shows that there is a need for more 
experiments to explain the role of LPA during AKI. The unavailability of specific receptor 
antagonist is a limiting factor for the studies aiming to discover which receptors are involved 
in LPA signaling. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
57 
 
3. Hypothesis 
It was clearly demonstrated previously that LPA1 receptor blockade protects against 
development of kidney fibrosis in course of UUO and DN [164, 165, 324]. Moreover, LPA 
production is elevated from obstructed kidneys [164]. These findings have some clinical 
relevance since increased LPA levels were described in patients with CKD and plasma levels 
of ATX are associated with kidney lesions in patients with DN [301, 302]. In addition, 
elevated LPA was found in effluent accumulated in kidneys with obstructed ureters [173] and 
in urine of patients with DN [316].  
In apparent contradiction to the profibrotic action in CKD, LPA was reported to protect 
kidneys against AKI. Two reports demonstrated that treatment with exogenous LPA preserves 
kidney function and structure upon I/R-induced AKI [330, 331].  
Analysing these information a question could emerge: how the same molecule could perform 
protection of kidneys on one hand and cause kidney fibrosis on the other hand? It is important 
to remember here that the two forms of kidney pathologies are different entities. Even though 
they share the same clinical presentation of lost kidney function and some pathogenetic 
mechanisms (notably the inflammation), they are however quite different in the velocity of 
the disease development, in the level of the reversibility and outcomes. If the AKI is an acute 
condition with the rapid development of clinical presentations that is potentially reversible, 
CKD develops over years and once the process of fibrosis in the organ is launched no 
regression could be expected. We hypothesize hereby that LPA could be differently involved 
in the pathogenesis of AKI and CKD: it protects in course of acutely developed AKI and in 
opposite, cause disease progression in course of long lasting CKD. To test this hypothesis we 
studied the role of LPA in both kidney pathologies, CKD and AKI. We studied LPA 
involvement in subtotal or 5/6 nephrectomy (SNX) model of CKD (Part 1) and the possible 
protective role of LPA in endotoxemia-induced AKI (Part 2).  
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4. Results and discussion  
4.1 LPA and CKD  
4.1.1 Bibliographic context and objectives  
LPA is considered as a profibrotic molecule in various organs (lungs, skin, kidney, etc.). 
Before the start of this study causative involvement of LPA in kidney fibrosis was initially 
demonstrated in UUO model [164] and has recently been demonstrated in DN model [324]. 
The metabolic pathways leading to increased urinary LPA described in UUO-induced kidney 
fibrosis and DN are not well characterized. Tsutsumi et al described increased renal ATX and 
AGK expression in parallel with increased choline producing activity of urine in obstructed 
kidneys of rats with UUO-induced kidney fibrosis, suggesting possible involvement of these 
enzymes in increased LPA production upon obstruction [173]. However, this hypothesis was 
not confirmed with experiments specifically targeting ATX or AGK (genetically or 
pharmacologically).   
The UUO model recapitulates all the key features of fibrogenic response in kidneys including 
activated inflammatory response, increased production of pro-fibrotic cytokines and growth 
factors, appearance of myofibroblasts with excessive accumulation of ECM proteins followed 
by progressive tubular loss and peritubular capillary rarefaction [303]. However the very rapid 
installation of fibrosis in kidney upon UUO differs from progressive appearance of CKD in 
human. Other limitations of the model are the compensation by the normal contralateral 
kidney and the absence of urine from the damaged kidney [303]. In contrast to UUO, subtotal 
or 5/6 nephrectomy model mimics progressive renal failure and is characterized by 
glomerulosclerosis accompanied by TIF and tubular atrophy that emerge about 2 week after 
surgery. Functional changes such as decreased GFR and proteinuria and increased systemic 
arterial pressure are prominent [335].  
The objectives of the first part of the thesis were to 
1) Investigate the involvement of LPA in this more progressive model of CKD. 
2) Study the changes in the renal production of LPA through analysis of both urinary LPA 
and the renal expression of enzymes involved in LPA metabolism in remnant kidneys 5 
months after sub-total nephrectomy. 
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4.1.2 Results 
 
Study of the LPA involvement in subtotal nephrectomy model of CKD and changes of its 
local metabolism. 
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Abstract Increased incidence of chronic kidney disease 
(CKD) with consecutive progression to end-stage renal 
disease represents a significant burden to healthcare sys-
tems. Renal tubulointerstitial fibrosis (TIF) is a classical 
hallmark of CKD and is well correlated with the loss of 
renal function. The bioactive lysophospholipid 
lysophosphatidic acid (LPA), acting through specific G-
protein-coupled receptors, was previously shown to be 
involved in TIF development in a mouse model of unilat-
eral ureteral obstruction. Here, we study the role of LPA in 
a mouse subjected to subtotal nephrectomy (SNx), a more  
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chronic and progressive model of CKD. Five months after 
surgical nephron reduction, SNx mice showed massive 
albuminuria, extensive TIF, and glomerular hypertrophy 
when compared to sham-operated animals. Urinary and 
plasma levels of LPA were analyzed using liquid chroma-
tography tandem mass spectrometry. LPA was significant-
ly increased in SNx urine, not in plasma, and was signif-
icantly correlated with albuminuria and TIF. Moreover, 
SNx mice showed significant downregulation in the renal 
expression of lipid phosphate phosphohydrolases (LPP1, 2, 
and 3) that might be involved in reduced LPA bioavail-
ability through dephosphorylation. We concluded that SNx 
increases urinary LPA through a mechanism that could 
involve co-excretion of plasma LPA with albumin 
associated with a reduction of its catabolism in the kidney. 
Because of the previously demonstrated profibrotic activ-
ity of LPA, the association of urinary LPA with TIF 
suggests the potential involvement of LPA in the devel-
opment of advanced CKD in the SNx mouse model. 
Targeting LPA metabolism might represent an interesting 
approach in CKD treatment. 
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Introduction 
 
Increased incidence of chronic kidney disease (CKD) 
with consecutive progression to end-stage renal disease  
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(ESRD) that necessitates renal replacement therapy rep-
resents a major burden to healthcare systems [7]. CKD is 
encompassing a number of heterogeneous disorders 
affecting the structure and function of the kidney. They all 
lead to a steady decline in nephron numbers that trigger 
multiple adaptive mechanisms, which can be-come 
dysadaptive and lead to profibrotic changes within the 
kidney. Fibrosis, the process of uncontrolled healing with 
excess accumulation of extracellular matrix, is a hallmark 
of CKD and is well correlated with future decline of renal 
function. Development of fibrosis in kidney tissue is a 
complex process and comprises pro-gressive development 
of tubulointerstitial fibrosis (TIF), glomerulosclerosis, and 
loss of glomerular and peritubular capillaries [14]. As most 
renal diseases are associated with renal fibrosis, the 
development of treat-ments aiming to slowdown, halt, or 
even better, reverse fibrosis holds a great potential in the 
fight against ESRD. The multitude of events and factors 
involved in the development of renal fibrosis is reflected 
by the large number of experimental reports showing the 
potential anti-fibrotic effects of a number of strategies and 
com-pounds [11, 12]. However, the only currently 
clinically available drugs that have shown to slowdown the 
pro-gression of CKD are the inhibitors of the renin angio-
tensin system (RASi). Unfortunately, even when treated 
with RASi, CKD continues to progress. Alternative 
molecules or therapies are thus necessary. 
 
Lysophosphatidic acid (LPA) is a lysophospholipid 
composed of a glycerol backbone with a phosphate head 
group at sn-3 position and a single ester-linked fatty 
acid chain (C16:0, C18:0, C18:1, C20:4) at sn-1 or sn-2 
position. Three major pathways are responsible for LPA 
synthesis: hydrolysis of lysophosphatidylcholine (LPC) 
by a soluble lysophospholipase D (autotaxin, ATX), 
deacylation of phosphatidic acid by phospholi-pase A1 
or A2 (PLA1 or PLA2), and phosphorylation of 
monoacylglycerol phosphate by an acylglycerol kinase 
(AGK) [1]. In contrast, the main LPA catabolic pathway 
of LPA is its dephosphorylation by lipid phosphate 
phosphohydrolase (LPP) that exists as three major sub-
types (LPP1, LPP2, and LPP3) [2, 4]. LPA has been 
shown to be present in various biological fluids includ-
ing plasma and urine. While plasma LPA mainly origi-
nates from hydrolysis of LPC by ATX, whether its 
presence in urine results from plasma excretion or from 
a local production in kidney remains poorly understood.  
LPA is a bioactive lipid ligand of specific G-protein-
coupled receptors (LPA1 to LPA6) that exerts a  
 
profibrotic action in several organs including the lung, 
skin, or kidney [6, 16–18]. The causal involvement of 
LPA in the development of kidney fibrosis was demon-
strated in a mouse model of accelerated development of 
TIF induced by unilateral ureteral obstruction (UUO). 
We and others demonstrated that UUO-mediated renal 
fibrosis can be prevented by transgenic invalidation or 
pharmacological blocking of the LPA1 receptor [16]. 
Although the UUO model induces renal inflammation, 
fibroblast activation, and accumulation of extracellular 
matrix in the tubulointerstitium, it probably does not 
really mirror the progressive appearance of CKD ob-
served in humans because of the rapidity of installation 
of the disease and the functional compensation by the 
contralateral kidney [8].  
Subtotal nephrectomy, or the so-called 5/6 nephrec-
tomy (SNx) or remnant kidney model, recapitulates the 
key features of nephropathy due to nephron reduction 
that characterizes most human CKD progression. The 
massive reduction of renal tissue due to SNx triggers 
excessive compensatory mechanisms of remaining 
nephrons that lead to hypertension, hyperfiltration, 
glomerulosclerosis, TIF, and CKD [22].  
In the present work, we studied the possible 
involve-ment of LPA in the development of CKD 
associated with SNx in mouse. 
 
 
Materials and methods 
 
Animals Female FVB/N mice were used because 
they were described as more susceptible to develop 
CKD following SNx [13, 15]. FVB/N mice were 
purchased from Janvier (Le Genest Saint Isle, 
France) and housed in pathogen-free, temperature-
controlled environment with a 12-h/12-h light/dark 
cycle. Animals had free access to food and tap water. 
All experiments were conducted in accordance with 
National Institute of Health guidelines for the care 
and use of laboratory animals and were approved by 
a local ethics committee (CEEA#122). 
 
Subtotal (5/6) nephrectomy (SNx) Subtotal (5/6) ne-
phrectomy was performed on 8-week-old mice. Animals 
were anesthetized with 2 % isoflurane. The right kidney 
was exposed, decapsulated, and removed through flank 
incision. Next, the left kidney was ex-posed through flank 
incision and was decapsulated to avoid ureter and adrenal 
damage. Upper and lower poles 
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were resected and weighed. In parallel, control animals 
underwent sham surgery by incision and suturing the 
two flanks (SHAM). After surgery, animals were re-
placed into cages and were sacrificed 5 months later. 
Before sacrifice, the mice were placed in metabolic 
cages for 12 h to collect urine. Mice were euthanized by 
pentobarbital injection after 6 h fasting. Blood was 
drawn by intra-cardiac puncture and collected in hepa-
rinized tubes (Microvette Hép-Lithium, Sarstedt, 
Marnay, France) to avoid platelet aggregation. Ice-cold 
blood was then centrifuged for 5 min at 1500×g and 
upper phase plasma was collected and immediately 
frozen at −80 °C. The remnant kidney was removed, 
and a portion of renal cortex was immediately immersed 
in liquid nitrogen and stored at −80 °C for further RNA 
extraction and RT-PCR analysis. The remaining kidney 
was immediately fixed in Carnoy’s solution (2 % ferric 
chloride in ethanol/chloroform/acetic acid 48/24/8) and 
embedded in paraffin for histological analysis. 
 
Measurement of urinary albumin and creatinine 
concentration The concentration of creatinine in urine 
was measured by the colorimetric method of Jaffe ac-
cording to the protocol Creatinine Assay Kit (Bio Assay 
Systems). The concentration of urinary albumin was 
measured by ELISA using the AlbuWell kit (Exocell). 
 
Histological analysis Four-micrometer kidney sections 
were deparaffinized in toluene and rehydrated by a 
series of ethanol baths containing decreasing concentra-
tions of ethanol. For anti-collagen III immunohisto-
chemistry, endogenous peroxidase activity was blocked 
with S2001 (Dako, Trappes, France) to reduce non-
specific binding of the antibodies; the sections were 
covered with a saturation buffer (1 % milk). Next, 
sections were incubated for 45 min at room temperature 
with rabbit primary murine anti-collagen III antibody 
(1/250th, reference BP8014, Acris, Herford, Germany) 
followed by incubation with the secondary rabbit anti-
IgG antibody (DAKO) coupled to horseradish peroxi-
dase (HRP). Next, the sections were covered with di-
aminobenzidine (Dako, Trappes, France), the chromo-
genic substrate of HRP. Finally, sections were counter-
stained by hematoxylin (DakoCytomation, Trappes, 
France) and examined under light microscope. For M a 
s s o n’s t r i c h r o m e , s t a i n i n g s e c t i o n s w e r 
e deparaffinized and rehydrated as described above and 
sequentially incubated with hematoxylin-eosine (2 min), 
picric acid (30 s), culvert fuchsin (5 min), 
 
phosphomolybdic acid (2 min), and finally, with aniline 
blue dye solution (5 min). Slides were dehydrated, em-
bedded in microscopic slides, and examined. Image 
analysis was performed using the ImageJ software 
(https://imagej.nih.gov/ij/). Collagen III quantification 
was performed by measuring the ratio of the collagen 
III-specific stained area to the total kidney section area. 
The glomerular area was analyzed by measuring the 
area of 50 glomerules in the sections stained by 
Masson’s trichrome. 
 
LC/MS-MS quantification of LPA and LPC species in  
plasma and urine LPA and LPC species were extracted  
from urine (150 μL) and plasma (10 μL) using 1-  
butanol containing 50 ng of LPA 17:0 and LPC 17:0  
as internal standards. Detection was conducted by LC/  
MS-MS using an Agilent 1290 Infinity HPLC system  
(Agilent Technologies) coupled on-line to an Agilent  
6460 triple quadrupole MS (Agilent Technologies)  
equipped with electrospray ionization source.  
Quantification was conducted through comparison with  
calibration curves of synthetic lipid standards: LPA  
16:0, LPA 17:0, LPA 18:0, LPA 18:1, LPA 18:2, LPA  
20:0, LPA 20:4, LPC 16:0, LPC 18:0, LPC 18:1, LPC  
20:0, LPC 22:0, and LPC 24:0. More details on the 
method and its validation are provided in 
supplementary files. 
 
RNA analysis Total RNA was isolated from snap frozen 
mouse kidneys. Tissue fragments were lysed mechani-
cally by TissuLyser (MM301, Retsch) in RLT buffer 
containing 1/100 of β-mercaptoethanol. Reverse tran-
scription and PCR amplification were performed as 
previously described [19]. Primer sequences are listed 
in Table 1. The hypoxanthine phosphoribosyltransferase 
(HPRT) mRNA was used as a reference gene.  
Normalization of gene expression was calculated ac-
cording to the following formula: 2(Ct HPRT-Ct gene of 
interest) where Ct corresponds to the number of cycles  
needed to generate a fluorescent signal above a 
predefined threshold. 
 
Statistical analysis Continuous variables were given 
as mean ± SE. Comparisons were conducted with 
unpaired Mann-Whitney test. Association between 
variables was analyzed by using the Spearman rank 
correlation test. A P value <0.05 was considered 
statistically significant: *P < 0.05, **P < 0.01, ***P 
< 0.001, ****P < 0.0001; ns as nonsignificant.  
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Table 1 PCR primer sequences    
     
Mouse gene Forward Reverse 
     
 acylglycerol kinase (AGK) GTGTTTGGCAACCAGCTCATT GCTGCGGGATTGAGAAAGAC 
 autotaxin (ATX) TCCGTGCATCGTACATGAAGA CAGGACCGCAGTTTCTCAATG 
 cell surface glycoprotein F4/80 TGACAACCAGACGGCTTGTG GCAGGCGAGGAAAAGATAGTGT 
 collagen type 1 (COL1) TGTGTGCGATGACGTGCAAT GGGTCCCTCGACTCCTACA 
 collagen type 3 (COL3) AAGGCGAATTCAAGGCTGAA TGTGTTTAGTACAGCCATCC 
   TCTAGAA 
 connective tissue growth factor (CTGF) GGCATCTCCACCCGAGTTAC GATTTTAGGTGTCCGGATGCA 
 hypoxanthine phosphoribosyltransferase TGGCCATCTGCCTAGTAAAGC GGACGCAGCAACTGACATTTC 
 (HRPT)    
 kidney injury molecule-1 (KIM-1) TAGAGACACGGAAGGCAACC TGCTGCTACTGCTCCTTGTG 
 lipid phosphate phosphatase-1 (LPP1) GGGAGACTGGGCAAGACTCTT CACTCGAGAAAGGCCCACAT 
 lipid phosphate phosphatase-2 (LPP2) CGCGATCCAACTTCAACAACT CAGCCCCGAACAGAAAGGT 
 lipid phosphate phosphatase-3 (LPP3) CCATCCTGGCGATCATTACAG AAAGGAAGCATCCCACTTGCT 
 nephrin (npsh1) ATGGGAGCTAAGGAAGCCACA CCACACCACAGCTTAACTGTC 
 neutrophil gelatinase-associated GGACCAGGGCTGTCGCTACT GGTGGCCACTTGCACATTGT 
 lipocalin (NGAL)    
 phospholipase A1 (PLA1) GGCGCTCGGAACAAAGC CGCAGGACAGCGCTGAT 
 phospholipase A2 group 2D (PLA2g2D) TGAAGATCGATGGATGCAAGAG GATAGTGCCCTGGGAGATGCT 
 phospholipase A2 group 2E (PLA2g2E) GGACGAGACGGATTGGTGTT CTCCAGGCGGCCATAGC 
 phospholipase A2 group 4 (PLA2g4) CCAAAGGCACCGAGAATGA TCGCTCACCAAGGCCATTA 
 podocin (npsh2) CCCTGAAGTTCTAGATGATTCCATAA AACAGCGTCGAGCAATTTCC 
  ATA   
      
 
 
Results 
 
Five months after surgery, SNx mice showed significant 
higher diuresis (6.1-fold) associated with a significant 
decrease in creatininuria, when compared to SHAM (Table 
2). SNx mice also showed a significant increase in 
albuminuria (9.2-fold when expressed in mg/L and 29.5-
fold when expressed as a ratio to urinary creatinine 
(uACR)) when compared to SHAM (Table 2). Body 
weight and blood glucose were not significantly differ-ent 
between SNx and SHAM mice (Table 2). Whereas the 
weight of the remnant kidney from SNx mice was not 
significantly different from the left kidney from SHAM 
mice, it showed significant higher glomerular surface area 
associated with significant higher interstitial collagen III 
content (Table 2 and Fig. 1). mRNA analy-sis showed that 
remnant kidneys from SNx mice also exhibited significant 
higher expression of renal injury genes (NGAL, KIM-1 
COL I, and COLIII) as well as of the inflammatory gene 
F4/80 when compared to SHAM (Table 3). Moreover, SNx 
mice also exhibited signifi-cant lower expression of the 
glomerular specific genes  
 
 
npsh1 (nephrin) and npsh2 (podocin), when compared 
to SHAM (Table 3). These results are in agreement with 
previous reports [15] showing that SNx leads to a strong 
impairment of kidney function associated with inflam-
mation, TIF, and glomerular damage.  
LC/MS-MS analysis of urine lysophospholipid com-
position showed increased concentration of five differ-
ent molecular LPA species (LPA16:0, LPA18:0, 
LPA18:1, LPA18:2, and LPA20:4) in SNx when com-
pared to SHAM mice (Fig. 2a, b). This was associated 
with significant increase in urine concentration of six of 
lysophosphatidylcholine (LPC) molecular species 
(LPC16:0, LPC18:0, LPC18:1, LPC20:0, LPC22:0, and 
LPC24:0; Fig. 2c, d). Urinary LPA and LPC were 
expressed as a ratio to urinary creatinine in order to 
adjust for urine dilution. In contrast to urine, the plasma 
levels of LPA and LPC species were not significantly 
different between SNx and SHAM mice (Fig. 3a, b). 
These results indicated that SNx led to a urine-specific 
alteration in lysophospholipid levels.  
Correlation analysis showed that total urinary LPA 
and LPC levels were significantly associated with TIF 
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Table 2 Body weight, organ weight, and urine composition of sham- and SNx-operated mice  
 
  Sham   SNX    
         
  Mean ±SEM n Mean ± SEM n P value 
        
 Body weight (g) 23.3±0.2 10 24 ± 1 5 ns 
 Left kidney weight (mg) 154 ± 5 10 167 ± 11 5 ns 
 Blood glucose (mg/dl) 128 ± 15 11  119 ± 13 5 ns 
 Diuresis (ml/18 h) 0.6 ± 0.1 11  4 ± 1 4 *  
 Urinary creatinine (mg/L) 672 ± 69 11  264 ± 45 9 ***  
 Urinary albumin (mg/L) 24 ± 3 11  218 ± 39 9 **  
 Urinary albumin/creatinine ratio (mg/g) 37 ± 5 11  1082 ± 254 9 **  
 Mean renal glomerular area (μm2) 2632 ± 91 6  4946 ± 333 4 **  
 Renal collagen III staining (% total surface) 11 ± 1 9  35 ± 5 10 **  
          
 ns not significant         
 *P<0.05, **P<0.01, ***P<0.01          
 
and uACR, but not with the glomerular surface area 
(Table 4). These results indicated that SNx-mediated 
increase of urinary lysophospholipids was correlated 
with the intensity of kidney damage.  
Analysis of kidney mRNA expression showed that 
the SNx remnant kidney exhibited significant lower 
 
A SHAM SNX  
 
expression of the three main LPA anabolic enzymes, 
PLA1, AGK, and ATX, when compared to kidneys 
from SHAM-operated animals (Fig. 4a–c). SNx rem-
nant kidney also exhibited significant lower expression 
of the three main LPA catabolic enzymes, LPP1, LPP2, 
and LPP3, when compared to kidneys from SHAM- 
 
B  
 
 
 
 
 
 
 
 
 
 
 
C D 
SHAM SNX 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 Histological features of kidney damage. Masson trichrome 
staining (a) and measurement of glomerular area (SHAM: n = 6; 
SNx: n = 4; b). Arrows localize glomeruli. Immunohistochemical 
 
 
 
 
 
 
 
 
 
 
 
detection of collagen III (c) and measurement of collagen III-
positive stained area (SHAM: n = 9; SNx: n = 10; d). Picture 
magnification, ×400. Scale 0.05 mm. Values are mean ± SEM  
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Table 3 Renal gene expression in sham- and SNx-operated mice  
 
Genes Gene expression       P value 
        
  mRNA/HPRT mRNA (×10,000)     
           
  Sham   SNX      
          
  Mean ± SEM n Mean ± SEM n   
        
 npsh1 2294 ± 218 10 670 ± 202 10 ****  
 npsh2 12,544 ± 960 10 6268 ± 1523 10 *  
 KIM-1 1641 ± 863 10 5480 ± 1529 10 *  
 NGAL 594 ± 140 10 16,407 ± 6018 10 *  
 COL1 545 ± 72 10 2394 ± 576 10 *  
 COL3 1438 ± 153 10 11,510 ± 2954 10 **  
 F4/80 125 ± 16 10 238 ± 32 10 **  
             
 
operated animals (Fig. 4d–f). Moreover, SNx remnant 
kidney exhibited no significant in PLA2g4, and signif-
icant higher expression of two isoforms of secreted 
PLA2 (sPLA2g2D and sPLA2g2D) when compared to  
 
kidneys from SHAM-operated animals (Fig. 4g–i). 
These results indicated that SNx led to altered expres-
sion of the enzymes involved in renal lysophospholipid 
metabolism. SNx remnant kidney also exhibited signif-
icant lower expression of the LPA receptor subtypes, 
LPA1, LPA2, LPA3, and LPA4, with no change in 
LPA5 and LPA6 (Fig. 1S). These results indicated that 
SNx is not associated with hyper sensitization of the 
kidney to LPA. Therefore, the contribution of LPA in 
SNx-mediated renal fibrosis is likely through 
modulation of its renal production rather through an 
increase in its renal sensitivity. 
 
 
 
Discussion 
 
Our hypothesis was that LPA could be involved in the 
development of CKD in the SNx mouse model. As 
previously reported [15, 20, 21] and confirmed in the 
present study, SNx model is characterized by a strong 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 Influence of SNx on urinay LPA and urinary LPC. The 
concentration of six LPA (a) and LPC species (c) was quantified 
by LC/MS-MS in urine from sham- and SNx-operated mice. Total  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
urinary LPA (b) and total urinary LPC (d) correspond to the 
sum of all species for each lysophospholipid class. Values are 
mean ± SEM of five to nine animals per group 
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Fig. 3 Influence of SNx on plasma LPA and plasma LPC. The 
concentration of six LPA (a) and LPC species (c) was quantified 
by LC/MS-MS in plasma from sham- and SNx-operated mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total plasma LPA (b) and total plasma LPC (d) correspond to 
the sum of all species for each lysophospholipid class. Values 
are mean ± SEM of seven to nine animals per group 
 
impairment in kidney function associated with major 
alterations in kidney structure such as TIF and 
glomer-ular damage. Our results indicate that SNx 
enhances urinary LPA excretion without changing its 
plasma levels. In addition, the urinary LPA levels are 
signifi-cantly correlated with albuminuria and TIF. 
Quantification of urinary LPA is expressed as a ratio 
to urinary creatinine. This is of current use in clinical 
chemistry and allows correcting for urine dilution. 
 
However, it is particularly useful under conditions of 
normal kidney function with unchanged creatinine ex-
cretion. When considering the data of Table 2, urinary 
creatinine is decreased after SNx; however, the diuresis 
is increased by 6.1-fold. Combining the data from Table 
2 allows estimating total creatinuria to 0.403 mg/18 h 
and 1.056 mg/18 h in SHAM and SNx, respectively. 
This means that the increase in albumin and LPA 
urinary excretion is still higher than described 
 
Table 4 Correlation of urinary lysophospholipids with albuminuria, TIF, and glomerular area  
 
  Urinary lysophospholipids       
          
  (nmole/g creatinine)        
          
  Total LPA   Total LPC     
          
  P value Spearman r  P value Spearman r 
        
Urinary albumin/creatinine ratio (mg/g) 0.00003 0.883 0.00020 0.801  
Renal collagen III staining (% total surface) 0.00386 0.733 0.00058 0.820  
Mean renal glomerular surface (μm2) 0.13611 0.724 0.11070 0.714  
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Fig. 4 Influence of SNx on renal expression of enzymes involved 
in LPA metabolism. mRNAs encoding for phospholipase A1 
(PLA1) (a), acylglycerol kinase (AGK) (b), autotaxin (ATX) (c), 
lipid phosphatephosphatases (LPP1–3) (d, e, f), cytosolic 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
phospholipase A2 (cPLA2g4A) (g), and 
secretedphospholipases A2 (sPLA2g2D and sPLA2g2E) (h, i) 
were quantified in the kidney of sham- and SNxoperatedmice. 
Values are mean ± SEM of 10 to 11 animals per group 
 
 
in the manuscript. Previous reports from our laboratory 
and others showed that LPA participates in TIF devel-
opment in UUO rodent models, through activation of 
the LPA1 receptor [16]. Therefore, we propose that the 
profibrotic activity of LPA could participate to the de-
velopment of SNx-associated CKD.  
LPA is present in plasma and urine, and our results 
show that SNx alters its concentration exclusively in 
urine. Whereas the origin of plasma LPA has clearly 
been established (i.e., ATX-mediated hydrolysis of LPC 
[3]), the origin of urinary LPA remains unclear. The 
presence of a given molecule in urine usually results 
from combined mechanisms of plasma filtration and 
local production within the kidney. Similarly with other 
lipids present in the plasma, LPA is bound to trans-
porters such as albumin or lipoproteins. SNx is associ-
ated with severe albuminuria, and our results show that  
 
 
urinary LPA is closely correlated with albuminuria. SNx-
mediated increase in urinary LPA could therefore result, at 
least in part, from its co-filtration with albumin from 
plasma to urine. Nevertheless, our results show that renal 
expression of several enzymes involved in LPA 
metabolism is altered by SNx. This suggests that changes 
in renal LPA production might also contribute to its SNx-
mediated increase in urine. The hypothesis is in agreement 
with previous reports showing that renal production of 
LPA is increased following UUO [16] as well as in 
glomeruli of mice with CKD associated with diabetic 
nephropathy [9]. Tsutsumi et al. previously found that the 
LPA concentration increases in urine that accumulates in 
the kidney following UUO in rat, and this was associated 
with increased renal expression of ATX and AGK, two 
enzymes involved in LPA synthesis [20]. Our results show 
that, conversely to UUO, renal 
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ATX and AGK are downregulated by SNx. We also 
observed a downregulation of PLA1, and no change in 
PLA2g4, two other potential LPA synthetic enzymes. 
Therefore, these observations suggest that ATX, AGK, 
PLA1, and PLA2g4 are unlikely responsible for SNx-
mediated increase in urinary LPA. On the other hand, 
our results show that SNx led to a clear downregulation 
of the lipid phosphate phosphatase (LPP1, LPP2, and 
LPP3) that are catabolic enzymes involved in 
dephosphosphorylation and inactivation of LPA [2, 5]. 
Based on those observations, we propose that SNx-
induced increase in urinary LPA could be explained, at 
least in part, by a reduction of its catabolism in kidney 
with the consequence of its increased bioavailability in 
urine.  
Our results indicate that, in parallel to urinary LPA, 
urinary LPC is also increased by SNx and is correlated 
with albuminuria and TIF. This suggests that, as for 
LPA, LPC could also be involved in the development of 
CKD. LPC, mainly derived from PLA2-dependent 
deacylation of phosphatidylcholine, is abundant in plas-
ma as a major component of oxidized low-density lipo-
proteins and is recognized as a carrier of fatty acids, 
glycerol, and choline between tissues. Our results show 
that SNx induces a clear upregulation of the renal ex-
pression of two potential LPC-producing enzymes, 
PLA2g2D and PLA2g2E. We propose that these en-
zymes might, among others, play a role in SNx-induced 
urinary LPC. LPC is a modulator of inflamma-tion and 
immunity with a connection to atherosclerosis. LPC has 
recently been demonstrated to participate to 
glomerulosclerosis by favoring infiltration of foam cells 
into glomeruli [10]. LPC was also shown to increase in 
urine that accumulates in kidney following UUO in rat 
[20]. Our results on SNx-mice reinforce the possible 
involvement of LPC in CKD through a possible impact 
on TIF and kidney function.  
In conclusion, since the SNx model is known to 
recapitulate the key features of human CKD [22], the 
involvement of LPA and LPC in human 
nephropathies could therefore be considered. If our 
hypothesis is cor-rect, the enzymes involved in the 
metabolism of LPA and LPC might represent 
potential targets for the treat-ment of CKD. 
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Supplements. 
LC/MS-MS  quantification of LPA and LPC species in plasma and urine. 
Chemicals and reagents.1-Butanol was purchased from Sigma Aldrich. Ammonium Formate (>99%), 
Formic acid (FA) and Methanol HPLC-grade (MeOH) were from Sigma Aldrich. Synthetic lipid standards: 
LPA 16:0, LPA 17:0, LPA 18:0, LPA 18:1, LPA 18:2, LPA 20:0, LPA 20:4, LPC 16:0, LPC 17:0, LPC 18:0, 
LPC 18:1, LPC 20:0, LPC 22:0, LPC 24:0 were purchased from Avanti Polar Lipids. Water used in this 
study was purified on a milliQ system (Millipore). 
Lipid extraction.Urine (150 μL) or plasma (10μl) volume was made up to 500 μL with deionized water and 
extracted with 500 μL non-acidified 1-Butanol containing 50 ng of LPA 17:0 as internal standards. Non-
acidified 1-butanol was preferred to acidified 1-butanol to avoid artificial production of LPA due to acid-
mediated hydrolysis from other phospholipids as previously demonstrated[1-3]. The samples were vortexed 
every 30 minutes for 2 h before centrifugation at 10.000 g for 20 minutes. The upper phase was transferred to 
a new tube and evaporated to dryness under reduced pressure using a Rotavapor. The extract was dissolved 
in 160 μL MeOH then filtrated on a 0.45 μmpolyterafluoroethylene membrane filter. The filtrate was 
evaporated and dissolved in 20 μL MeOH.  The extract was then stored at−20 °C before LC-MS/MS 
analysis.  
LC/MS-MS.High performance liquid chromatography was performed using an Agilent 1290 Infinity (Agilent 
Technologies) equipped with an auto sampler, a binary pump and a column oven. The analytical column was 
an Acquity UPLC BEH-C8 (100 x 2,1 mm, 1,7 廘m) (Waters) maintained at 25 °C. The separation on C8 
column allows a short time analysis (8 minutes including column equilibration time). The mobile phases 
consisted of Water, FA and MeOH (20:0,5:79,5; v/v/v) (A) and MeOH, FA (99,5:0,5, v/v) (B). The two 
mobile phases contained 5 mM ammonium formate. The gradient was as follows: 0% B at 0 min, 0% B at 1 
min, 100% B at 2 min, 100% B at 5 min, 0% B at 6 min and 0% B at 8 min. The flow rate was 0,2 mL/min. 
The auto sampler was set at 5 °C and the injection volume was 5 μL. The HPLC system was coupled on-line 
to an Agilent 6460 triple quadrupole MS (Agilent Technologies) equipped with electrospray ionization 
source. Electrospray ionization (ESI) was performed in positive (Pos) ion mode for LPC and negative (Neg) 
ion mode for LPA using two separate acquisitions. Optimization of MS parameters was performed manually 
for each standard. After optimization, the source parameters used were as follows: source temperature was 
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set at 300°C, nebulizer gas (nitrogen) flow rate was 10 L/min, sheath gas temperature was 300°C, sheath gas 
(nitrogen) flow rate was 12 L/min and the spray voltage was adjusted to +4000 V. Collision energy and 
Fragmentor voltage were optimized for each LPA and LPC species (Table S1). The most abundant daughter 
ions generated by tandem mass spectrometry fragmentation of each species were 153 and 184 m/z for LPA 
and LPC respectively (Table S1). Analyses were performed in Selected Reaction Monitoring detection mode 
(SRM) using nitrogen as collision gas. Finally, peak detection, integration and quantitative analysis were 
done using MassHunterQqQ Quantitative analysis software (Agilent Technologies) and Microsoft Excel 
software.  
Calibration curves.LPA 17:0 and LPC 17:0 was mixed at a concentration of 1000 ng/mL and 200 ng/mL 
respectively in MeOH and used as internal standard (IS) solution. Stock solution of LPA and LPC species 
(except IS) was prepared in MeOH at 1000 ng/mL and 200 ng/mL respectively, then ten calibration points 
(dilution by half) were prepared in MeOH. These ten solutions were mixed with a fixed concentration of IS 
solution to prepare the following LPA standard solutions: 1.95, 3.9, 7.8, 15.6, 31.25, 62.5, 125, 250 and 500 
ng/mL containing 100 ng/mL of IS for LPC; and 3.9, 7.8, 15.6, 31.25, 62.5, 125, 250, 500 and 1000 ng/mL 
containing 500 ng/mL of IS for LPA. Calibration curves were calculated by the ratio between analyte and 
internal standard peak area. Finally the linearity, the limit of detection (LOD) and the limit of quantification 
(LOQ) were determined for the 12 compounds (Table S2). The standard curve of each LPA and LPC species 
fitted to a linear regression model with correlation factors over 0.99 (Table S2).  
Accuracy and precision.To determine the repeatability and precision of the method, 3 samples containing 
(3.91, 31.25 and 250 ng/mL for LPC, 7.8, 62.5 and 500 ng/mL for LPA) were analyzed in triplicate on the 
same day with back-calculated amount using standard curves. This procedure was repeated at day 1, day 7 
and day 15. RSD (%) and accuracy (%) within one sample run (intra-day) and between sample runs (inter-
day) was determined for each species of LPA and LPC (Table S3 and S4). Intra-day accuracies were ranging 
from 98.1% to 107.6% for the LPA species (Table S3) and from 96.6 to 119.2% for the LPC species. 
Variations for 3 injections was  ≤ 5.6% for LPA species and <13.4% for LPC species. Inter-day variations 
were assessed by re-analyzing the same sample every 7 days (n=3). Accuracies were between 94.6 and 
112.2% for LPA species, and between 99.8 and 110.0% for LPC species, indicating suitable reproducibility 
of the protocol.  
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Matrix effect and extraction efficiency.Urine or plasma lipid extracts were spiked (post spiked samples) 
with stock solution of LPA and LPC at two concentrations (500 ng/mL and 62.5 ng/mL for LPA ; 250 ng/mL 
and 31.25 ng/mL for LPC ) and IS solution (50 μL). Each sample was analyzed in triplicate. In parallel, a 
separate set of stock solution of LPA, LPC and IS solution was directly analyzed in triplicate. Matrix effect 
was determined as the percentage difference between each LPA and LPC standard peak area with and 
without plasma and urine extracts. Urine extract without spiking was analyzed to quantify area of “natural” 
analyte and subtract this one to post spiked samples. Matrix effect of urine was rather low with a signal 
recovery of varying from 58.7 to 74.9%, and from 60.9 to 83.4% for LPA and LPC species respectively 
(Supplementary Table 5 and 6). Matrix effect of plasma was more important with a signal recovery varying 
from 23.7 to 68.8 %, and from 21.9 to 42.9% for LPA and LPC species respectively  (Supplementary Table 
6). To calculate extraction efficiency, plasma and urine (n = 3) were spiked with IS solution (50 μL) and 
stock solution of LPA and LPC at two concentrations (500 ng/mL and 62.5 ng/mL for LPA ; 250 ng/mL and 
31.25 ng/mL for LPC ) before 1-butanol extraction (pre spiked sample). The sample analysis was performed 
in triplicate and the extraction efficiency was determined as the percent difference between pre spiked and 
post spiked samples. Urinary and plasma matrix effect and extraction efficiency were calculated for each 
compound (Tables S5 and S6). Despite the differences in matrix effect, extraction yields of LPA and LPC 
species were high (65 to 99%) and not different between urine and plasma (Table S5 and S6). 
References 
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[3] Onorato JM, Shipkova P, Minnich A, Aubry AF, Easter J and Tymiak A (2014) Challenges in accurate 
quantitation of lysophosphatidic acids in human biofluids. J Lipid Res  55: 1784-96 
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Table S1. HPLC retention time (RT) and selected reaction monitoring detection mode (SRM) conditions for 
each LPA and LPC species 
 
Compound RT Precursor ion 
(m/z) 
Product ion 
(m/z) 
Fragmentor 
(V) 
Colision 
energy (V) 
LPA (16:0) 3.89 409 153 140 20 
LPA (18:0) 4.21 437 153 140 20 
LPA (18:1) 3.99 435 153 140 20 
LPA (18:2) 3.76 433 153 140 20 
LPA (20:0) 4.53 465 153 140 22 
LPA (20:4) 3.77 457 153 140 20 
LPA (17:0) 4.05 423 153 140 20 
      
LPC (16:0) 3.67 496 184 110 30 
LPC (18:0) 4.17 524 184 120 30 
LPC (18:2) 4.21 533 184 120 30 
LPC (18:1) 3.90 522 184 120 30 
LPC (20:0) 4.43 552 184 120 30 
LPC (22:0) 4.68 580 184 120 30 
LPC  (24:0) 4.96 608 184 120 30 
LPC (17:0) 3.98 510 184 120 30 
 
Table S2. Calibration curve equation, coefficient of determination (r2), limit of detection (LOD), 
and limit of quantification (LOQ) for each LPA and LPC species. 
 
Species Curve equation r2 
LOD 
(ng/mL) 
LOQ 
(ng/mL) 
LPA 16:0 y = 8.399681E - 004 * x - 0.009931 0.998 0.98 1.95 
LPA 18:0 y = 9.002772E - 004 * x - 0.010106 0.998 0.49 0.98 
LPA 18:1 y = 6.852677E - 004 * x - 0.008400 0.998 0.98 1.95 
LPA 18:2 y = 0.001747 * x - 0.021235 0.998 0.49 0.98 
LPA 20:0 y = 6.721874E - 004 * x - 0.008460 0.998 0.98 1.95 
LPA 20:4 y = 0.001408 * x - 0.016777 0.998 0.49 0.98 
LPC 16:0 y = 0.004262 * x - 0.028598 0.997 0.06 0.12 
LPC 18:0 y = 0.005037 * x - 0.031414 0.998 0.06  0.12 
LPC 18:1 y = 0.005391 * x - 0.032945 0.998 0.06 0.12 
LPC 20:0 y = 0.004247 * x - 0.020694 0.999 0.06 0.12 
LPC 22:0 y = 0.003138 * x - 0.013611 0.999 0.12 0.24 
LPC 24:0 y = 0.001920* x - 0.006924 0.999 0.12 0.24 
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Table S3.Intra- and inter-day precision and accuracy of assay method for each LPA species. 
 
  Intra-day Inter-day 
Species (ng/ml) Measured RSD 
% 
Accuracy 
% 
Measured RS
D % 
Accuracy 
% 
LPA 16:0 7.81 7.56 ± 0.43 5.6 103.2 7.71 ± 0.57 7.4 101.3 
62.5 57.75 ± 0.21 0.4 107.6 54.90 ± 0.50 0.9 112.2 
500 483.50 ± 7.76 1.6 103.3 461.47 ± 8.54 1.9 107.7 
LPA 18:0 7.81 7.78 ± 0.10 1.3 100.3 8.17 ± 0.28 3.4 95.4 
62.5 59.61 ± 0.22 0.4 104.6 58.76 ± 1.44 2.5 106.0 
500 480.31 ± 2.71 0.6 103.9 481.87 ± 75.79 15.7 103.6 
LPA 18:1 7.81 7.96 ± 0.20 2.5 98.0 7.52 ± 0.32 4.3 103.7 
62.5 59.61 ± 0.50 0.8 105.5 58.13 ± 0.40 0.7 107.0 
500 481.03 ± 1.56 0.3 103.8 476.80 ± 13.11 2.7 104.6 
LPA 18:2 7.81 7.77 ± 0.21 2.6 100.4 7.85 ± 0.17 2.2 99.5 
62.5 59.24 ± 0.45 0.8 105.2 57.18 ± 0.87 1.5 108.5 
500 480.77 ± 1.37 0.3 103.8 467.07 ± 4.37 0.9 106.6 
LPA 20 :0 7.81 7.62 ± 0.13 1.7 102.3 8.23 ± 0.44 5.3 94.6 
62.5 59.75 ± 0.27 0.5 104.4 56.47 ± 0.73 1.3 109.6 
500 478.35 ± 1.54 0.3 104.3 492.97 ± 17.78 3.6 101.4 
LPA 20 :4 7.81 7.87 ± 0.18 2.3 99.2 7.76 ± 0.14 1.8 100.6 
62.5 59.02 ± 0.23 0.4 105.6 57.51 ± 0.51 0.9 108.0 
500 481.16 ± 0.87 0.2 103.8 464.29 ± 13.50 2.9 107.1 
 
Table S4.Intra- and inter-day precision and accuracy of assay method for each LPC species. 
  Intraday Interday 
Species (ng/ml) Measured RSD 
% 
Accuracy 
% 
Measured RSD 
% 
Accuracy % 
LPC 16:0 3.91       3.63 ± 0.01 0.3     107.1       3.52 ± 0.05     1.4     110.0 
31.25      29.21 ± 0.18 0.5     106.5       28.25 ± 0.15     0.5     109.6 
250   239.76 ± 3.23 1.3     104.1       245.41 ± 3.56   1.5     101.8 
LPC 18:0   3.91       3.79 ± 0.03 1.6     103.2       3.63 ± 0.01     0.3     107.2 
31.25      29.23 ± 0.10 0.9     106.5       29.49 ± 0.10     0.3     105.6 
250   243.01 ± 1.31 0.3     102.8       242.92 ± 3.06   1.3     102.8 
LPC 18:1   3.91       3.65 ± 0.06 0.8     106.6       3.78 ± 0.01     0.3     103.3 
31.25      28.90 ± 0.26 0.3     107.5       29.17 ± 0.11     0.4     106.7 
250   243.54 ± 0.75 0.5     102.6       243.88 ± 0.45   0.2     102.4 
LPC 20:0   3.91       3.57 ± 0.17 4.8     108.6       3.75 ± 0.04     1.1     104.1 
31.25      27.16 ± 1.23 4.5     113.1       29.59 ± 0.15     0.5     105.3 
250   249.05 ± 2.17 0.9     100.4       245.36 ± 2.70   1.1     101.9 
LPC 22:0   3.91       3.43 ± 0.9 8.5     112.1       3.75 ± 0.05     1.3     104.1 
31.25      26.05 ± 1.75 6.7     116.6       29.62 ± 0.18     0.6     105.2 
250   255.99 ± 1.93 0.8     97.6        247.12 ± 4.22   1.7     101.2 
LPC 24:0 3.91       3.42 ± 0.246 13.4    112.5       3.74 ± 0.16     4.3     104.3 
31.25      25.22 ± 2.03 8.0     119.2       29.75 ± 0.23     0.8     104.8 
250   258.54 ± 8.02 3.1     96.6        250.57 ± 6.86   2.7     99.8 
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Table S5. Matrix effect and extraction efficiency for LPAs 
 
 Urine Plasma 
 Matrix effect Yield extraction Matrix effect Yield extraction 
LPA species (ng/ml) (ng/ml) (ng/ml) (ng/ml) 
 500 62.5 500 62.5 500 62.5 500 62.5 
16 :0 58.75 ± 3.9 68.9 ± 4.1 92.3 ± 4.6 83.3 ± 1.9 23.7 ± 1.7 21.4 ± 3.2 72 ± 7.6 86 ± 5.2 
18 :0 70.67 ±6.9 83.40 ± 5.9 98.3 ± 2.3 94.1 ± 2.8 36.4 ± 30.9 36.7 ± 1.9 78 ± 4.8 89 ± 3.8 
18 :1 64.6 ± 5 73.5 ± 4.2 91.7 ± 3.8 82.4 ± 2.6 27.8 ± 1.6 27.6 ± 3.2 69 ± 6.5 83 ± 4.3 
18 :2 60.9 ± 3.5 68.1 ± 4.2 92.1 ± 5.0 80.1 ± 2.4 26 ± 1.3 26.4 ± 3.2 74 ± 3.5 89 ± 5.4 
20 :0 85.0 ± 5.0 74.9 ± 6.0 93.6 ± 3.1 82.6 ± 3.8 66.8 ± 2.9 69.3 ± 6.6 65 ± 6.6 74 ± 5 
20 :4 59.1 ± 4.2 66.3 ± 4.2 91.4 ± 5.2 78.3 ± 2.4 25.5 ± 2.3 25.6 ± 1.3 72 ± 3.4 86 ± 4.2 
17 :0 (IS) 65.6 ± 4.0 58.5 ± 3.2 94.7 ± 4.2 89.2 ± 2.5 31 ± 1.5 27 ± 1.2 74 ± 4.4 91 ± 1.8 
 
 
 
 
Table S6. Matrix effect and extraction efficiency for LPCs 
 
 Urine Plasma 
 Matrix effect Yield extraction Matrix effect Yield extraction 
LPC species (ng/ml) (ng/ml) (ng/ml) (ng/ml) 
 250 31.2 250 31.2 250 31.2 250 31.2 
16 :0 42.3 ± 2.4 36.6 ± 5.2 92.3 ± 3.8 87.0 ± 4.6 25.1 ± 4.1 26.6 ± 3.9 97.4 ± 0.9 80.3 ± 6.5 
18 :0 35.0 ± 2.2 37.6 ± 4.6 99.7 ± 2.2 97.3 ± 1.9 28.9 ± 4.5 30.2 ± 2.3 96.9 ± 2.0 67.4 ± 0.8 
18 :1 42.3 ± 2.4 36.6 ± 5.2 94.9 ± 1.9 95.1 ± 3.6 31.5 ± 0.8 38.6 ± 5.8 96.4 ± 1.4 70.0 ± 1.0 
20 :0 41.5 ± 2.3 56.8 ± 3.1 92.6 ±1.9 87.8 ± 4.7 24.2 ± 2.6 42.9 ± 8.8 76.6 ± 9.3 92.3 ± 6.5 
22 :0 43.1 ± 1.8 62.0 ± 3.2 90.7 ± 2.1 86.6 ± 2.5 21.9 ± 1.7 38.3 ± 6.3 88.2 ± 8.3 89.6 ± 5.4 
24 :0 55.9 ± 3.4 79.9 ± 6.1 93.5 ± 3.2 90.2 ± 4.8 27.0 ± 2.1 33.8 ± 7.2 92.7 ± 6.5 89.5 ± 6.4 
17 :0 (IS) 42.5 ± 2.3 39.1 ± 2.5 93.7 ± 1.3 90.0 ± 2.9 34.6 ± 5.8 39.4 ± 4.3 88.6 ± 6.5 88.4 ± 1.2 
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Figure 1S.Influence of SNx on renal expression of LPA receptor subtypes. mRNAs encoding for LPA1, 
LPA2, LPA3, LPA4, LPA5 and LPA6 were quantified in the kidney of SHAM- andSNx-operatedmice. 
Values are mean ± SEM of 10 to 11 animals per group.  
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4.1.3 Conclusions and discussion 
4.1.3.1 The main results and conclusions 
x We showed here that SNX is associated with a strong increase in the level of different 
species of LPA and LPC in urine that were significantly correlated with kidney fibrosis and 
albuminuria. These data indirectly indicate that LPA and LPC could be involved in the 
development of kidney fibrosis after sub-total nephrectomy.    
x We also observed that the renal expression of the enzymes involved in LPA synthesis 
(AGK, ATX and PLA1) were significantly reduced by SNX. Expression of the LPA 
degrading enzymes (LPP1, LPP2 and LPP3) was also decreased. This indicates that in course 
of kidney fibrosis LPA metabolism is changed in kidneys, and  decreased local degradation of 
LPA could be responsible for its increased availibility. 
 
4.1.3.2 Discussion 
4.1.3.2.1 What is the origin of urinary LPA? 
 
LPA is found in plasma where it circulates bound to albumin and other carriers. While plasma 
LPA is mainly produced by ATX, the origin of urinary LPA remains poorly understood. As 
for other compounds, the presence of LPA in urine can result either from its excretion or from 
its local synthesis in kidney. In our study we found that increased urine LPA level in SNX 
mice is positively correlated with increased albuminuria. This can indicate that increased 
urine LPA can at least partially result from its co-excretion with albumin. In parallel we found 
no changes in plasma LPA levels. The increased urinary LPA without changes in its plasma 
concentration let us to think that increased urinary LPA could also result from changes in 
kidney LPA metabolism. To test this hypothesis we measured the kidney expression of 
different enzymes, potentially involved in LPA production. As discussed in the article 
decreased kidney expression of enzymes involved in LPA synthesis (ATX, MAGK, PLA1 
and PLA2g4) indicates that these enzymes are likely not responsible for increased urinary 
LPA after subtotal nephrectomy. In opposite, decreased expression of three isoforms of LPA 
catabolic enzymes LPPs suggests that increased urine LPA could be the result of its decreased 
degradation in remnant kidneys. Interestingly, data from our team showed that LPP1 and 
LPP3 were also down-regulated in kidneys upon obstruction-induced fibrosis (Jean-Philippe 
Pradère, unpublished data). Our hypothesis that LPA production is increased from kidneys 
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after sub-total nephrectomy now requires further verification. One approach could be to 
measure ex vivo production of LPA levels by explants prepared from the remnant kidneys. 
Decreased expression of LPP1 and LPP3 was described in several types of cancer and over-
expression of LPP1 and/or LPP3 in ovarian and breast cancer cells increases LPA hydrolysis, 
inhibits cell proliferation and colony-forming activity, increases apoptosis, reduces LPA-
induced cell migration [123, 124, 179]. Regulation of enzyme expression in biological 
systems with prescribed compounds seems rather difficult approach however it was shown 
that gonadotropin-releasing hormone analogs increase LPP expression in ovarian cancer cells 
[336]. Therefore it could be interesting to test whether the use of these compounds could 
increase LPPs expression in kidney cells. If it is a case it could be interesting to test whether 
increase in LPPs expression in vivo will change urinary LPA concentrations and the 
development of fibrosis in our model of CKD.  
In parallel to increased urinary LPA and LPC, their plasma levels were not changed upon sub-
total nephrectomy. Plasma levels of lysophospholipids were not changed in UUO-induced 
kidney fibrosis [173] or in patients with DN as well (accepted manuscript). This finding is in 
contradiction with a recent report, where metabolomic analysis of plasma samples from rats 
with two different models of CKD and patients with various forms of CKD revealed increased 
amounts of two molecular species of LPA (16:0 and 18:2) that were proposed as biomarkers 
for the discrimination of CKD patients from healthy subjects [301]. How could we explain 
that discrepancy of results from various studies regarding the association between CKD and 
plasma lysophospholipids? Plasma samples of the same species (human and rat) were 
analyzed in experiments with contradictory results regarding plasma levels of 
lysophospholipids. Moreover the same animal model of CKD (5/6 nephrectomy) was used. 
This can indicate that species-dependent and model-dependent factors could not account for 
the observed divergence of results. However, this disagreement of results remains 
unexplained. The increased urinary lysophospholipids without any changes in plasma level 
suggests that changes in urinary LPA and LPC levels are likely urine-specific. Therefore it 
can be proposed to test the different LPA and LPC species in urine as biomarkers able to 
discriminate CKD patients from healthy subjects. Future large-scale experiments with 
involvement of patients with different forms of CKDs and various animal models of the 
disease are required for the validation of urine LPA and LPC species as efficient biomarkers 
for CKD. 
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4.1.3.2.2 LPA receptors in subtotal nephrectomy-associated kidney fibrosis 
 
In parallel to positive correlation with the level of albuminuria, SNX-induced increased urine 
LPA levels are positively correlated with the intensity of TIF. Since LPA was previously 
shown as a fibrosis-promoting factor in kidney [164, 165, 324] we propose hereby that it 
could also be responsible for fibrosis development in SNX. Nevertheless, we measured 
mRNA expression changes of LPA receptors and found a decreased expression of LPA1-4 
and no changes in LPA5 and LPA6 expression in kidney from SNX mice. This could indicate 
that 5 months after subtotal nephrectomy sensitivity of kidney cells to LPA is not increased 
suggesting that fibrosis likely results from increased LPA levels. Although, knowledge about 
regulation of LPA receptors is scarce, it was demonstrated that they are prone to agonist-
induced phosphorylation followed by receptor internalization and receptor desensitization 
[337]. Other biological active molecules such as angiotensin II and EGF also could 
desensitize LPA receptors [338, 339]. Therefore we hypothesize that down-regulation of LPA 
receptors in remnant kidneys could reflect the desensitization processes induced by increased 
levels of LPA or other compounds that increase in fibrosis. Future studies are now required to 
test this hypothesis and the first step could be the study of LPA receptor expression in early 
stages of kidney fibrosis and its changes during disease progression. Since genetic ablation 
and pharmacological blockade of LPA1 receptor has been shown previously to attenuate 
kidney fibrosis [164, 165] it could be of  interest to study sub-total nephrectomy-induced 
kidney fibrosis in LPA1-/- animals and/or in animals treated with LPA1 receptor antagonist. 
Promotion of kidney fibrosis through LPA2 receptor signaling has also been proposed in vitro 
[165, 309]. Since specific LPA2 receptor antagonists are not available, the use of LPA2-/- 
could be an alternative strategy to test in vivo the LPA2 receptor involvement in kidney 
fibrosis. We found no changes in LPA5 and LPA6 expression whereas they were up-regulated 
in UUO-induced kidney fibrosis. Whether LPA5 and LPA6 play a role in kidney fibrosis is 
not known and could be interesting to test in future experiments.   
4.1.3.2.3 LPC in kidney fibrosis 
 
We demonstrated in our study that 5 months after subtotal nephrectomy, urinary LPC 
increases in parallel to LPA and that increased LPC levels are correlated with increased 
albuminuria. As for LPA, this could suggest that increased urine LPC could at least partially 
result from its coexcretion with albumin. However, we demonstrated here that 2 enzymes 
80 
 
(sPLA2g2D and sPLA2g2E) potentially involved in LPC production are up-regulated 
suggesting that LPC production from phosphatidylcholine (PC) by the action of PLA2 might 
contribute to its increased urine levels. This hypothesis is in agreement with a recent report 
where decreased PC levels in urine are described in parallel to increased urinary LPC in 
patients with focal-segmental glomerulosclerosis (FSGS) indirectly indicating that PLA2 
dependant degradation of PC indeed could contribute to increase in urinary LPC [340]. The 
hypothesis could be verified with the use of specific inhibitors of sPLA2 (LY315920) in mice 
with subtotal nephrectomy or other models of CKD. In addition, increased LPC levels are 
described in kidney glomerules of animals with DN and FSGS and in urine accumulated in 
kidneys after obstruction [173, 311, 341], however the biological role of increased LPC in 
kidneys and urine is poorly understood. We described here that increased urinary LPC 
correlates positively with TIF as well suggesting that LPC could be involved in development 
of kidney fibrosis. The underlying mechanisms of possible LPC-induced fibrosis are not well 
known. In vitro experiments demonstrated that LPC induces expression of adhesion 
molecules and chemokines in glomerular endothelial and mesangial cells and could lead to 
macrophage infiltration and glomerulosclerosis [341, 342]. In vivo experiments describing the 
role of LPC in kidney fibrosis are not available and the lack of specific LPC receptors is a 
limiting factor in this field of lysophospholipid research. 
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4.2 LPA and AKI 
4.2.1 Bibliographic context and objectives  
Previous reports demonstrated that treatment with exogenous LPA could protect against I/R-
induced damage of kidneys and heart [330, 331, 343]. In an apparent contradiction another 
report demonstrated that blockade of LPA receptors with the LPA1/3 antagonist protects 
against I/R-induced AKI [332]. These differences of the results indicate that more 
investigations are required to clarify the role of LPA in AKI.  
In parallel to these reports LPA was demonstrated to increase animal survival upon challenge 
with endotoxin and to protect against sepsis-induced damage of lung, liver and neuromuscular 
junction [262, 263, 344]. Since sepsis is one of the major causes of AKI, we were interested 
here whether LPA could protect against sepsis-induced AKI. LPS administration is one form 
of sepsis-induced AKI model. Such models are usually applied in small rodents and are well 
standardized. LPS triggers a local cell response in proximal tubular epithelial cells through 
binding to TLR4 receptors, which, together with similar responses elicited in extrarenal cells, 
promotes the expression of pro-inflammatory cytokines responsible for renal cell damage 
[345, 346]. Additionally, the production of reactive oxygen and nitrogen species as well as 
NO release causes hemodynamic alterations that also contribute to AKI [346].  
The objectives of the second part of the thesis were to 
1) Study whether LPS-induced AKI in mice could be counteracted by exogenous LPA.  
2) Test whether LPS treatment could influence the local renal metabolism of LPA. 
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4.2.2 Results 
 
Study of the LPA involvement in LPS-induced AKI and changes of its local metabolism. 
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Abstract 
Septic shock is the most common cause of acute kidney injury (AKI) but the underlying 
mechanisms remain unclear and no targeted therapies exist. Lysophosphatidic acid (LPA) is a 
bioactive lipid which in vivo administration was reported to mitigate inflammation and 
injuries caused by bacterial endotoxemia in liver and lung. The objective of the present study 
was to determine whether LPA can protect against sepsis-associated AKI. C57BL/6 mice 
were treated with LPA 18:1 (5mg/kg, i.p.) 1 hour before being injected with the endotoxin 
lipopolysaccharide (LPS) and AKI was evaluated after 24h. LPA significantly decreased the 
elevation of plasma urea and creatinine caused by LPS. In the kidney, LPA pre-treatment 
significantly reduced the up-regulation of inflammatory cytokines (IL-6, TNFα, MCP-1), and 
completely prevented down-regulation of peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha and up-regulation of heme oxygenase-1 caused by LPS. LPA also 
prevented LPS-mediated alterations of the renal mitochondrial ultrastructure. In vitro, pre-
treatment with LPA 18:1 significantly attenuated LPS-induced up-regulation of the 
inflammatory cytokines (TNFα and MCP-1) in RAW264 macrophages. Moreover, in vivo 
LPS-treatment lowered urinary LPA concentration and reduced LPA anabolic enzymes 
(autotaxin and acylglycerol kinase), and increased the LPA catalytic enzyme (lipid phosphate 
phosphatase 2) expression in the kidney cortex. In conclusion, exogenous LPA exerted a 
protective action against renal inflammation and injuries caused by bacterial endotoxemia. 
Moreover, LPS reduces the renal production of LPA suggesting that sepsis-associated AKI 
could be mediated, at least in part, by alleviation of the protective action of endogenous LPA. 
 
Key words: endotoxemia, kidney, lysophosphatidic acid, macrophages 
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Introduction 
Acute kidney injury (AKI) describes a multifactorial and complex clinical syndrome 
characterized by an acute decrease of renal function with accumulation of waste products and 
electrolyte imbalance [1]. AKI is associated with increased mortality and morbidity during the 
acute phase as well as in the long term. The incidence of AKI after general surgery is nearly 
1% whereas it can reach up to 70% in critically ill patients. So far no targeted therapies exist 
against AKI and all interventions are not specific. One of the most common causal factors of 
AKI in hospital intensive care units is septic shock. AKI occurs nearly in half of patients with 
sepsis and increases mortality six to eight times [2 , 3].  
Sepsis-induced AKI is often associated with renal hypoperfusion and ischemia but can also 
occur in the absence of major hemodynamic alterations [4 , 5 , 6]. The pathogenic 
mechanisms of sepsis-induced AKI involve renal microcirculatory changes, inflammation, 
endothelial dysfunction, coagulation disturbances and adaptive cell responses such as down-
regulating metabolism or cell cycle arrest [7].Sepsis-induced AKI is usually associated with 
lower rate of tubular apoptosis and necrosis than other forms of AKI linked to a reduction of 
oxygen consumption resulting from a dedifferentiation process associated with mitochondrial 
rarefaction that would shift the cells towards an energy-saving state [7]. A central mediator of 
renal resistance to AKI is PGC1α (peroxisome proliferator activated receptor gamma co-
activator-1-alpha) a master regulator of mitochondrial biogenesis and oxidative metabolism 
that contribute to renal functional recovery following kidney aggression [8 , 9]. 
Lysophosphatidic acid (LPA) is a lysophospholipid present in various biological fluids that 
can exert several biological activities through the activation of specific G-protein coupled 
receptors (LPA1 to LPA6) [10 , 11]. LPA is present in different physiological fluids including 
plasma and urine. The abundance of urinary LPA increases in kidney disease models 
including unilateral ureteral obstruction and 5/6 nephrectomy, and is correlated with renal 
fibrosis [12, 13]. LPA is synthesized by enzymes including lysophospholipase D (also named 
autotaxin), phospholipase A1 and A2 or acylglycerolkinase [10] and inactivated by 
dephosphorylation by lipid-phosphate phosphatases (LPP1, LPP2, LPP3) [14]. 
Previous reports have shown that AKI generated by ischemia-reperfusion of the kidney could 
be prevented by injecting LPA to the animals before surgery [15 , 16 , 17]. It was also shown 
that administration of LPA to mice exposed to severe endotoxemia or infection increases their 
survival and reduces organ damage other than the kidney (liver, neuromuscular junction) [18 , 
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19 , 20 , 21]. Moreover, exposure to endotoxin or ischemia was shown to alter LPA 
production in plasma and bronchoalveolar lavage fluid [21 , 22 , 23 , 24 , 25 , 26 , 27]. 
The objective of the present study was to assess whether LPA could exert a protective action 
on sepsis-induced AKI in vivo and in vitro.  
 
Methods 
Drugs. LPA18:1, LPA16:0 and LPA18:0 (Avanti Polar, GOGER, Paris, France) and LPS 
(LPS-EB Ultrapure, Invivogen, San Diego, USA) were solubilized in PBS supplemented with 
1% fatty acid free bovine serum albumin (BSA). This solution without the drugs was as 
control (vehicle, VH).  
Animals. Male C57BL6 mice (10 weeks old) were used for experiments that were purchased 
from Janvier (Le Genest Saint Isle, France) and housed in pathogen-free, temperature-
controlled environment with a 12-hour/12-hour light/ dark cycle. Animals had free access to 
food and tap water. All experiments were conducted in accordance with the Guide for the care 
and use of laboratory animals from the National Institute of Health and were approved by a 
local ethics committee (CEEA#122). Mice were injected with LPA 18:1 (5mg/kg, i.p.) 1 hour 
before i.p. injection of LPS at the dose of 10mg/kg (protocol 1) or 3 mg/kg (protocol 2). 
Control animals received 100μl of VH (VH group).  
In protocol 1, the mice were euthanized by pentobarbital injection 24 hours after LPS 
injection. Blood was drawn by intra-cardiac puncture and collected in heparinized tubes and 
stored on ice (Microvette Hép-Lithium, Sarstedt, Marnay, France). Ice-cold blood was then 
centrifuged for 5 minutes at 1500xg and upper plasma phase was collected and immediately 
frozen at -80°C. Kidney cortex (upper and lower poles) was dissected out. One part of kidney 
cortex was immediately immersed in liquid nitrogen and then stored at -80°C for future RNA 
extraction and RT-PCR analysis. Another part of kidney cortex was dedicated to transmission 
electron microscopy.  
In protocol 2, treated mice were placed into metabolic cages to collect urine after 9 and 24h, 
urine was centrifuged for 5 minutes at 3000xg and stored at -20°C for LPA quantification. 
The animals were then euthanized by pentobarbital injection to collect blood samples and 
kidneys as described in protocol 1. 
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Transmission electron microscopy. Kidney cortex was fixed with 2% glutaraldehyde in 
Sorensen phosphate buffer (0.1 M, pH 7.4) for 1 hour, washed with the Sorensen phosphate 
buffer for 12 hours and post fixed with 1% OsO4 in Sorensen phosphate buffer for 1 hour. 
Samples were dehydrated with increasing ethanol concentration (30%, 50%, 70%, 95%) until 
a 100% ethanol solution was reached and then subsequently stored for 30 min in a propylene 
oxide solution before being embedded in epoxy resin. After 24 h of polymerization at 60°C, 
ultrathin sections (70 nm) were mounted on 100 mesh collodion-coated copper grids and 
poststained with 3% uranyl acetate in 50% ethanol and with 8.5% lead citrate before being 
examined on a HT7700 Hitachi electron microscope at an accelerating voltage of 80 KV. A 
series of 10 photographs were taken at x7000 magnification.  
Measurement of plasma urea and creatinine concentration. Urea and creatinine levels 
were measured by colorimetric tests on a Pentra 400 analyzer (Horiba Medical, Grabels, 
France). 
LC-MS/MS quantification of LPA species in plasma and urine. LPA species were 
extracted from urine (150 μl) and plasma (10 μl) using 1-butanol containing 50 ng of LPA 
17:0 as internal standard as previously described [13]. Detection was conducted by LC-
MS/MS using an Agilent 1290 Infinity HPLC system (Agilent Technologies) coupled on-line 
to an Agilent 6460 triple quadrupole MS (Agilent Technologies) equipped with electrospray 
ionization source. Quantification was conducted through comparison with calibration curves 
of synthetic lipid standards: LPA 16:0, LPA 18:0, LPA 18:1, LPA 18:2, LPA 20:0, LPA 20:4, 
LPA 22:0, LPA 24:0. More details on the method and its validation are provided in [13]. 
Cell culture. The murine macrophage cell line RAW264.7 [28] was purchased from ATCC© 
(Molsheim, France). Cells were cultured in a humidified atmosphere of 5%CO2-95% O2 air at 
37°C. RAW264.7 cells were plated at a density of 1 x 105 cells/cm2 in 12 well plates and 
grown to 70-80% confluence (about 48h) in DMEM supplemented with 50 U/mL Penicillin, 
50 mg/mL Streptomycin and 10% heat-inactivated FBS. The cells were then serum-deprived 
for 24 h hours before being pretreated with 10 μM of LPA18:1 for 15 minutes before being 
exposed to LPS (100ng/ml) or VH. After 4 hours, the medium was collected to quantify 
TNFαconcentration, and the cells were washed once with PBS and total RNA was extracted 
and analyzed. 
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Quantification of TNFα. The concentration of TNFα in RAW264.7 cell culture medium 
(1/10 dilution) was measured using the CisbioBioassays’s mouse TNFα kit (Cisbio 
International, Bagnols/Ceze, France). 
RNA analysis. Total RNA was isolated from frozen kidney or cells using Qiagen RNEasy 
Plus Mini Kit (Qiagen, Valencia, CA) in accordance with manufacturer protocols. Reverse 
transcription and PCR amplification were performed on a FlexCycler2 (Analytik Jena Ag, 
Jena Germany) and StepOne Plus Real-Time PCR systems (Thermofisher,Asnières, France) 
respectively as previously described [29]. Primer sequences are listed in Table 1. The 
glyceraldehydes 3-phosphate dehydrogenase (GAPDH) mRNA was used as a reference gene. 
Normalization of gene expression was calculated according to the following formula: 
2(CtGAPDH-Ctgene of interest) where Ct corresponds to the number of cycles needed to generate a 
fluorescent signal above a predefined threshold. 
 
 
Statistical Analysis. Continuous variables were presented as mean ± SEM. Comparisons 
were made with unpaired Student’s t test where 2 groups of variables were compared and with 
analysis of variance (ANOVA) where more than 2 groups of variables were compared. A P 
value <0.05 was considered statistically significant: *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001.  
Mouse gêne Forward Reverse
Acylglcerol kinase (Agk) GTGTTTGGCAACCAGCTCATT GCTGCGGGATTGAGAAAGAC
Autotaxin (Atx) TCCGTGCATCGTACATGAAGA CAGGACCGCAGTTTCTCAATG
Glyceraldehyde 3-phosphate dehydrogenase (Gapdh)
TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG
Hemeoxygenase 1 (Ho-1) AGAAGGGTCAGGTGTCCAGA TGCCCTCTATCTCCTCTTCC
Interleukin 6 (Il6) GCCCACCAAGAACGATAGTCA CAAGAAGGCAACTGGATGGAA
Lipid phosphate phosphatase-1 (Lpp1) GGGAGACTGGGCAAGACTCTT CACTCGAGAAAGGCCCACAT
Lipid phosphate phosphatase-2 (Lpp2) CGCGATCCAACTTCAACAACT CAGCCCCGAACAGAAAGGT
Llipid phosphate phosphatase-3 (Lpp3) CCATCCTGGCGATCATTACAG AAAGGAAGCATCCCACTTGCT
Monocyte chemotacticprotein 1 (Mcp1) GCAGTTAACGCCCCACTCA CCAGCCTACTCATTGGGATCA
PPARγcoactivator 1α (Pgc1α) AAAGGATGCGCTCTCGTTCA GGAATATGGTGATCGGGAACA
Tumor necrosis factor α (Tnfα) ATGGCCTCCCTCTCATCAGT CACTTGGTGGTTTGCTACGA
Table 1. Sequences of the primers used in RT-PCR analysis.
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Results 
For the sepsis-induced AKI we employed for the major part of the study a classical LPS-
induction protocol using 10 mg/kg of LPS (protocol 1) [30]. However, most mice treated with 
10 mg/kg of LPS did not survive in metabolic cages necessary for the collection of urine, 
most likely due to the additional stress imposed by the cages. Hence for the collection of urine 
a lower dose (3 mg/kg) of LPS was used to induce AKI (protocol 2).  
LPA injection counteracts the deleterious effects of LPS on AKI. 
Using protocol 1 to induce AKI, LPS-treated mice showed a significant increase of plasma 
urea and plasma creatinine, when compared to control mice (VH) and LPA pretreatment 
significantly attenuated LPS effects (Figure 1A and B).  
 
  
LPS treatment significantly elevated the renal expression of the inflammatory cytokine genes 
IL-6, TNFα and MCP-1 and this was significantly attenuated by LPA (Figure 2A-C).  
A B
Figure 1. Influence of in vivo LPA and LPS treatments on plasma urea and creatinine. Mice were
injected with LPA 18:1 (5mg/kg, i.p.) 1 hour before injecting LPS (10 mg/kg, i.p.). Control animals
received 100μl of vehicle (VH). Blood was collected after 24h to measure plasma urea (A) and plasma
creatinine (B). The number of animal per group was 9, 9, 9 and 10 for VH, LPA, LPS and LPA/LPS
respectively. Values are means ± SEM. ANOVA analysis: *p<0.05, **p<0.01 and ***p<0.001.
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LPS treatment significantly reduced the renal expression of peroxisome proliferator-activated 
receptor gamma coactivator 1-alpha (PGC1-α) involved in mitochondriogenesis (Figure 3A). 
LPS also significantly increased the renal expression of heme oxygenase-1 (HO-1) involved 
in oxidative stress (Figure 3B). These effects were significantly attenuated by LPA (Figure 
3Aand B). Electron microscopy analysis showed that renal mitochondria from LPS-treated 
mice appeared swollen and vacuolated with a decrease in the number of dense granules when 
compared to control mice (Figure 3C).Those granules were proposed to correspond a local 
accumulation of cations inside mitochondria [31]. LPA almost completely restored the 
alterations of mitochondria ultrastucture generated by LPS (Figure 3C). 
A B
C
Figure 2. Influence of in vivo LPA and LPS treatments on renal expression of
proinflammatory cytokines. Mice were injected with LPA 18:1 (5mg/kg, i.p.) 1 hour before
injecting LPS (10 mg/kg, i.p.). Control animals received 100μl of vehicle (VH). Kidney cortex
was collected after 24h to measure the gene expression of IL-6 (A), TNFa (B) and MCP-1 (C).
The number of animal per group was 9, 9, 9 and 10 for VH, LPA, LPS and LPA/LPS
respectively. Values are means ± SEM. ANOVA analysis: *p<0.05, **p<0.01 and ***p<0.001.
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LPA displays direct anti-inflammatory properties on macrophages in vitro. 
To assess whether the anti-inflammatory effect of LPA could result from its direct action on 
macrophages, in vitro experiments were performed on the murine macrophage cell line 
RAW264.7. Exposition of those cells to LPS led to a massive release of TNFα in the culture 
medium (Figure 4A) and a massive increase in the expression of the inflammatory cytokine 
genes TNFα(Figure 4B), IL-6 (Figure C), and MCP-1 (Figure 4D). While pre-treatment with 
LPA 18:1 exerted no effect by itself, it significantly reduced LPS-induced TNFα release 
(Figure 4A) and gene expression (Figure 4B). LPA also reduced LPS-induced MCP-1 (Figure 
4D) but had no significant influence on LPS-induced IL-6 gene expression (Figure 4B). The 
most abundant LPA receptor subtypes expressed in RAW262.7 cells were LPA2 and LPA5 
(data not shown).  
 
 
 
B
CA VH LPA
LPS LPA/LPS
Figure 3. Influence of in vivo LPA and LPS treatments on renal mitochondria genes and structure.
Mice were injected with LPA 18:1 (5mg/kg, i.p.) 1 hour before injecting LPS (10 mg/kg, i.p.). Control
animals received 100μl of vehicle (VH). Kidney cortex was collected after 24h to measure the gene
expression of PGC1a (A) and HO-1 (B). The number of animal per group was 9, 9, 9 and 10 for VH,
LPA, LPS and LPA/LPS respectively. Values are means ± SEM. ANOVA analysis: *p<0.05, **p<0.01
and ***p<0.001. (C) Transmission electron microscopy of kidney slices (magnification x7000).
Representative of 5 to 7 images from 1 animal per group (arrows indicate dense granules).
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LPS reduces endogenous LPA production. 
Our next objective was to determine whether LPS could influence endogenous LPA 
production. For that LPA was quantified in urine and plasma using LC-MS/MS. For this part 
of the study protocol 2 was employed using 3 mg/kg of LPS to induce AKI [32]. The 
induction of AKI by this low dose was maintained (increased BUN and plasma creatinine, 
data not shown) and allowed maintaining the mice alive in metabolic cage. In these 
conditions, the urine concentration of LPA was significantly reduced (-47%) 9 hours after 
LPS injection when compared to VH (Figure 5A). LPS-induced reduction of urine LPA was 
further amplified (-67%) after 24h (Figure 5B). LPS-induced changes in urinary LPA mainly 
concerned LPA16:0, LPA18:1 and LPA18:2 (Figure 5C).  
A B
C D
Figure 4. Influence of in vitro LPA and LPS treatments on macrophage cytokines. RAW264.7
marcrophages in culture were serum-deprived for 24h before being pretreated with LPA18:1 (10 μM)
for 15 minutes and with LPS (100ng/ml) or vehicle (VH). After 4 hours, the release of TNFα in the
culture medium was quantified (A), and total RNA was extracted from the cells to measure the
expression of TNFα (B), IL-6 (C), and MCP-1 (D). Values are means ± SEM of 3 (A) and 4 (B, C, D)
separate experiments. ANOVA analysis: **p<0.01 ,***p<0.001 and ****p<0.0001.
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In contrast to urine, plasma LPA concentrations were not significantly modified by LPS 
injection (Figure 6).  
 
A B
C
9h 24h
Figure 5. Influence of LPS treatment on urine LPA content. Mice were injected with LPS (3
mg/kg, i.p.) (n=8). Control animals received 100μl of vehicle (VH) (n=8). The mice were placed into
metabolic cages to collect urine after 9 and 24h. LPA was quantified in urine by LC/MS-MS.
Concentration of total LPA (sum of LPA species) after 9 h (A) and 24h (B). (C) concentration of the
different LPA species from LPS-treated and control (VH) mice. Values are means ± SEM. Unpaired
student’s t-test: *p<0.05.
A B
Figure 6. Influence of LPS treatment on plasma LPA content. Mice were injected with LPS (3
mg/kg, i.p.) (n=8). Control animals received 100μl of vehicle (VH) (n=8). Blood was collected after
24h and plasma was prepared. LPA was quantified in plasma by LC/MS-MS. (A) total LPA (sum of
LPA species) concentration. (B) concentration of the different LPA species from LPS-treated and
control (VH) mice. Values are means ± SEM. Unpaired student’s t-test.
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LPS alters the renal expression of renal LPA metabolic enzymes.  
To assess whether LPS-mediated reduction of urine LPA could result from an alteration of 
renal LPA metabolism, the expression of the enzymes involved in LPA metabolism was 
measured in kidney cortex. LPS-treatment significantly reduced the expression of 2 anabolic 
enzymes, ATX and AGK (-22 and -23% respectively) when compared to control (Table 2). In 
parallel, LPS significantly increased (272%) the expression of the catabolic enzyme LPP2, 
while LPP1 and LPP3 subtypes remained unchanged (Table 2). 
 
 
 
 
Discussion 
Previous reports have shown that AKI generated by ischemia-reperfusion could be prevented 
by administration of exogenous LPA before surgery [15 , 16 , 17]. LPA was also shown to 
reduce the injury caused by LPS to liver and lung [18 , 19 , 20 , 21]. In the present work, we 
observed that LPA was able to mitigate several responses characteristic of LPS-induced AKI 
such as elevation of plasma urea and creatinine, up-regulation of renal cytokine expression, 
down-regulation of renal PGC1a, up-regulation of renal HO-1 and alteration of renal 
mitochondrial ultrastructure. From these observations, we can conclude that the protective 
effect of LPA against AKI is not limited to ischemia-reperfusion and can be extended to 
sepsis. 
Gene expression
Fold change over mean of VH
VH LPS
Genes Mean SEM n Mean SEM n P value
Atx 1,00 ± 0.05 8 0,78 ± 0.07 8 *
Agk 1,00 ± 0,08 8 0,77± 0,06 8 *
Lpp1 1,00 ± 0,09 8 1,23± 0,12 8 ns
Lpp2 1,00 ± 0,09 8 2,72± 0,28 8 ****
Lpp3 1,00 ± 0,14 8 1,43± 0,20 8 ns
Table2. Influence of in vivo LPS treatment on renal expression of LPA metabolic enzymes. Mice
were injected with LPS (3 mg/kg, i.p.) (n=8). Control animals received 100μl of vehicle (VH) (n=8).
Kidney cortex was collected after 24h to measure the gene expression of LPA metabolic enzymes.
Values are means ± SEM. Unpaired student’s t-test: *p<0.05, ****p<0.0001.
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Inflammation is a common feature of AKI whether it is induced by ischemia-reperfusion or 
sepsis, and its consequence is the propagation of renal damage. Indeed, the burst of pro-
inflammatory cytokines during the initial phase of sepsis stimulates renal cells (resident 
leucocytes, endothelial, and epithelial cells) and lead to platelet activation, microvascular 
dysfunction, hypoxia, and tissue damage [33 , 34 , 35]. Our results showed that LPA 
counteracts the pro-inflammatory action of LPS both in vivo in kidney and in vitro in cultured 
macrophages. Those results are in agreement with previous report showing that LPA inhibits 
bacterial endotoxin-shock through an anti-inflammatory signaling pathway in other organs 
[18]. Our results are also in agreement with previous reports showing that LPA is an 
important contributor of the anti-inflammatory action of albumin on renal tubular cells and 
macrophages [36]. Therefore, the protective activity of LPA against LPS-induced AKI could 
be mediated, at least in part, by its anti-inflammatory activity on macrophages. Nevertheless, 
we cannot exclude that LPA could also influence other hallmarks of sepsis-induced AKI such 
as macro- and micro-vascular dysfunctions, oxidative stress or mitochondrial defects [37]. 
Indeed, LPA was shown to increase endothelial resistance [38 , 39], a crucial process in 
vascular dysfunction. LPA was also reported to regulate mitochondrial fragmentation and 
fusion [40]. Interestingly, our work shows that LPA injection counteracts the swelling and 
vacuolization of mitochondria, and mitigates the down-regulation of PGC1a and the up-
regulation of HO-1 generated by LPS. Therefore, preservation of mitochondrial function and 
dynamics could also play a role in the protective effect of LPA against LPS-induced AKI.  
Our results show that LPS-treatment led to a reduction of LPA concentration in urine. To our 
knowledge, this has not been reported previously. The presence of a metabolite in urine 
results either from its excretion from plasma, or from its local production in kidney. In 
contrast to previous reports [21 , 27], we found no influence of LPS-induced AKI on the 
plasma LPA concentration. Moreover, we found that LPS-treatment altered the renal 
expression of several enzymes involved in LPA metabolism, suggesting that kidney could 
participate to the production of LPA in urine. Moreover, in view of the variation in the 
expression of these enzymes, the decrease in renal production of LPA result from a decrease 
in its synthesis by ATX or AGK and an increase in its degradation by LPP2. 
Our work shows that administration of exogenous LPA protects against LPS-induced AKI 
and that LPS-treatment reduces the level of endogenous LPA in urine as a possible reflection 
of a reduced production of LPA in kidney. We propose that basal renal production of LPA 
could exert a protective activity on kidney that could be alleviated during sepsis, and thereby 
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favoring AKI development. If this hypothesis is correct therapeutic strategies consisting in 
increasing renal LPA production could help to prevent sepsis-induced AKI. 
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4.2.3 Conclusions and discussion 
4.2.3.1 The main results and conclusions 
x We demonstrated here that LPA pretreatment mitigates LPS-induced elevation of 
plasma urea and creatinine, up-regulation of renal expression of inflammatory cytokines and 
HO-1, down-regulation of renal PGC1α and ultrastructural changes of mitochondria in 
kidneys. Therefore LPA-induced protection in course of AKI is not limited to I/R and could 
be extended to endotoxemia. 
x LPA pretreatment reduced LPS-induced up-regulation of inflammatory cytokines in 
cultured macrophages indicating that targeting of these cells by LPA could be responsible for 
the overall anti-inflammatory action demonstrated in kidneys in course of endotoxemia-
induced AKI.  
x We showed that urinary LPA is decreased in sepsis-induced AKI and this is associated 
with a down-regulation of the LPA producing enzymes ATX and AGK and an up-regulation 
of the LPA degrading enzyme LPP2 in kidney. This indicates that in course of endotoxemia, 
LPA availability in kidney could be decreased due to its’ altered metabolism, especially 
decreased production and/or increased degradation. 
 
4.2.3.2 Discussion 
4.2.3.2.1 How LPA protects against endotoxemia-induced AKI? 
 
We found here that LPA is able to protect against endotoxemia-induced AKI indicating that 
previously observed LPA-exerted organ protection during sepsis could be extended to 
kidneys. However that protection requires to be verified in future experiments with the use of 
more specific functional tests of kidney function (ex: measurement of GFR). We observed 
that LPA blocks the LPS-induced up-regulation of inflammatory cytokines in kidney. 
Activated inflammatory reaction is a central event in the establishment and progression of 
endotoxemia-induced AKI. Therefore we hypothesized here that LPA-induced protection 
against endotoxemia-induced AKI could at least partially be explained by its anti-
inflammatory action. The cells targeted by LPA are not known. Since macrophages play an 
important role in the induction and progression of the inflammatory reaction we tested 
whether LPA could directly block the LPS-induced activation of these cells. We found that 
LPA partially blocks LPS-induced up-regulation of inflammatory cytokines in RAW264.7 
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cell line. This result supports that the blockade of the pro-inflammatory action of LPS by LPA 
could participate in the protective action of LPA against endotoxemia-induced AKI. It could 
be interesting next to test whether LPA could also block the activation of primary 
macrophages from kidneys. For the next step it could be an interesting approach to test 
whether the LPA-induced blockade of macrophage activation is responsible for the protection 
exerted by LPA in course of LPS-induced AKI in vivo.  
It was previously shown that LPA protects tubular epithelial cells from serum-deprivation-
induced apoptosis and induces proliferation of these cells [305-307]. In addition, the tubular 
cells are activated by LPS and/or by pro-inflammatory cytokines in sepsis-induced AKI. 
Therefore tubular epithelial cells could be another cell target of LPA in AKI. The histological 
alterations of tubular epithelial cells upon sepsis-induced AKI are scarce. It was shown 
previously that vacuolization of proximal tubular epithelial cells upon septic injury reflects 
mostly the mitochondrial damage [37]. We found here that structural changes of mitochondria 
in kidneys of animals challenged with endotoxin are reversed by LPA pretreatment, 
suggesting that LPA could act on tubular cells and reverse LPS-induced changes. This 
hypothesis requires further verification through in vitro experiments on tubular epithelial cells 
in culture.  
It was shown that sepsis triggers adaptive responses in tubular epithelial cells [36, 43]. One of 
the consequences of these responses are the metabolic changes required to preserve the source 
of cell energy. Mitochondria are the central elements of the regulation of this response and the 
PGC1α is one of the molecular switches that regulate the metabolic activity of tubular cells. 
We found that LPA pretreatment reverses LPS-induced down-regulation of PGC1α, which in 
combination with the protection of ultrastructural changes of mitochondria could indicate that 
LPA-induced protection of kidney function could involve changes in the mitochondrial 
dynamic.  
Other cell types, such as endothelial cells, could also be involved in the LPA-induced kidney 
protection. This hypothesis is supported by a studies showing that LPA increases endothelial 
barrier resistance and decreases permeability of endothelial layer [347, 348]. Since endothelial 
dysfunction and transmigration of leukocytes is a crucial event in inflammatory reaction in 
sepsis-induced AKI, it would be interesting to test whether LPA increases the resistance of 
endothelial layer composed of the cells from kidney microvasculature. It could also be of 
interest to test whether LPA treatment decreases the permeability of capillaries in vivo. 
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4.2.3.2.2 Urinary LPA decreases in endotoxemia 
 
We showed here for the first time that LPA concentration in urine decreases in LPS-induced 
AKI. In addition the plasma concentration of LPA remains unchanged. This last finding is in 
apparent contradiction with a recent study, where increased plasma LPA was found in animals 
with sepsis [264]. However in that study the cecal ligation and puncture was used in ICR mice 
to induce the sepsis. This difference in animal species and disease models could possibly be 
responsible for the divergence of results in LPA plasma concentration in these studies and 
requires further investigations. In addition to decreased LPA levels in urine we also found a 
down-regulation of the LPA producing ATX and AGK combined with an up-regulation of the 
LPA degrading LPP2 in kidney. These results suggest that changes in the local metabolism of 
LPA could at least partially be responsible for its decreased urinary levels. These hypothesis 
could be verified by measuring the ex vivo production of LPA by explants prepared from 
septic kidneys.  
We found here that exogenous LPA could exert protective effects during endotoxemia-
induced-AKI, whereas its endogenous production in kidneys is decreased upon endotoxemia. 
Based on these data we hypothesize that the basal production of LPA in kidney could exert a 
constitutive protection of kidney cells which is alleviated by endotoxemia. If this hypothesis 
is true it could be of particular interest to determine how to maintain renal LPA production. 
One possibility would be to increase its synthesis. Since ATX is an inducible enzyme and 
VEGF and retinoic acid could increase its expression [349, 350], it could be interesting to test 
whether ATX up-regulation in kidney cells could result in increased production of LPA. With 
the same logic it could be interesting to test whether the blockade of LPP2 could be effective 
in increasing LPA production from kidney cells. If these strategies are proven in vitro, next 
step could be to test their efficacy in vivo. There are reports showing that addition of LPC18:1 
and LPA18:1 in the chow of animals increases tissue levels of LPA18:1, LPA18:2, LPA20:4 
in jejunum and liver and increases their plasma concentration [351]. Moreover, ATX was 
shown to be responsible for the production of mentioned LPA species from LPC18:1. 
However the consequence of that diet on kidney and urinary LPA levels has not been 
investigated in that report and would deserve to be investigated in the future. If addition of 
lysophospholipids into diet could induce LPA production in kidney it could be an alternative 
strategy to elevate levels of possibly protective LPA species in kidney. In next step 
applicability of this approach in human should be verified.  Since LPA is known as a 
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profibrotic agent and also is involved in the processes of tumorigenesis and atherosclerosis, 
the implication of this approach could be limited and the long-term complications of diet 
induced increase in LPA species in the body should be examined in animal models.  
Nevertheless, the described diet induced concentration changes take long time to develop and 
could have only preventive implication in septic patients who are at high risk for the AKI 
development.  
Decreased kidney production of LPA could also have some adaptive meaning. Since LPA 
promotes proliferation of tubular epithelial cells, its decreased levels in sepsis could act as a 
signal that triggers cell cycle arrest, which ensures kidney function recovery after the initial 
injurious factor has alleviated. The hypothesis requires further verification.   
The decrease in urinary LPA associated with endotoxemia-induced AKI could be of 
importance. It is well known that current clinical detection of AKI is based on the measured 
levels of plasma creatinine as a reflection of GFR reduction. But plasma creatinine is often a 
late marker of the disease and rather reflects the kidney function decline when the AKI has 
already been established. Therefore the research of new biomarkers for the early detection of 
AKI is of particular attention of researchers. We observed here for the first time that 9 hours 
after the endotoxin injectuion the urinary LPA concentration in mice is decreased. However, 
urinary LPA changes in earlier stages of the endotoxemia are unknown and it would be 
interesting to test whether urinary LPA decline could be observed earlier than 9 hours after 
induction of endotoxemia. The next step could be the detection of urinary LPA changes in 
patients with sepsis. If the decreased urinary LPA is observed in patients with sepsis as well, 
it would be interesting in next step to make a cohort of septic patients, follow them and 
evaluate the AKI development in a prospective study and make multiple measurements of 
urinary LPA levels in different times after induction of sepsis. This approach could let us to 
examine whether the decrease in urinary LPA could have a prognostic value in patients with 
sepsis and would let to discriminate the septic patients who are at higher risk for AKI 
development.   
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5. Summary 
The initial question of the thesis was to check whether LPA is involved in the sub-total 
nephrectomy model of CKD and whether it could exert some protection in course of AKI.  
We found that 5 months after sub-total nephrectomy LPA production increases in remnant 
kidneys and that increased urinary LPA is positively correlated with kidney fibrosis. This data 
combined with previous reports let us to suggest that LPA is a profibrotic molecule that 
uniformly promotes kidney fibrosis in various forms of CKD. In parallel we found that 
exogenous LPA protects from kidney dysfunction in endotoxemia-induced kidney injury 
possibly through the reduction of inflammatory reaction in kidney. Moreover, kidney 
production of LPA decreases during endotoxemia. There is an apparent contradiction in 
effects of LPA between CKD and AKI. If in CKD it acts as a deleterious factor that promotes 
kidney fibrosis, in AKI it protects from kidney damage. The inflammation is a key component 
in the pathogenesis of both AKI and CKD and LPA is differentially involved in acute and 
chronic inflammatory processes (discussed in 2.7.4). Therefore the contradictory involvement 
of LPA in AKI and CKD could be explained by the different activity state of immune and 
inflammatory cells and/ by activation of different LPA receptors and downstream signaling 
pathways in the processes of acute and chronic inflammation in AKI and CKD respectively. 
It is known that in some patients with AKI kidney function do not recover completely and 
they are in higher risk for the development of CKD later in life. Various mechanisms are 
responsible for the development of CKD following AKI (discussed in 1.2.3.1.1). As discussed 
previously, decreased production of LPA could have an adaptive role, since it could possibly 
trigger the cell cycle arrest that limits energy expenditure. However, it is known also that cells 
arrested in G2/M phase of cell cycle produce increased amounts of pro-fibrotic cytokines 
(especially TGFβ and CTGF) that leads to further fibrosis development [104]. Therefore an 
interesting hypothesis rises: if the decrease in local LPA production upon sepsis-induced AKI 
is prolonged, the arrested cells could produce pro-fibrotic cytokines that reflects the transition 
from adaptive cell response to the dysadaptive. As a consequence, kidney fibrosis develops. 
The first step to test the possible role of LPA in the progression from AKI to CKD could be 
the thorough follow-up of animals that survive an AKI episode with the measurement of urine 
LPA changes during the follow-up and analyze of the CKD development later in life. If 
decreased LPA production could indeed be responsible for the progression of AKI to CKD, it 
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could be interesting next to explore the mechanisms which are responsible for prolonged 
decrease in LPA production after AKI episode.  
We found here that the kidney metabolism of LPA is changed both in AKI and CKD. The 
cellular sources of LPA in kidney are not described. Theoretically tubular epithelial cells, 
glomerular cells (mesangial cells, podocytes, endothelial cells), macrophages and 
myofibroblasts could produce LPA. The separation of different cell types and further in vitro 
analysis of these cells from control and fibrotic kidneys could be one approach to check the 
cellular sources of LPA in kidney. 
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